Document:

Exhibit 10.19

 

SECOND AMENDED AND
RESTATED MANAGEMENT SERVICES AGREEMENT

 

This Second Amended
and Restated Management Services Agreement (this “Agreement”) is entered into as of January 17, 2017, by and
among BCM Advisory Partners LLC, a Delaware limited liability company (“Broadband Advisory”), Broadband Capital
Partners LLC, a Delaware limited liability company (“Broadband Capital”, and, together with Broadband Advisory,
 “Broadband”), and Immunome, Inc., a Delaware corporation (the “Company”).

 

WHEREAS, the Company
and Broadband Advisory are parties to that certain Management Services Agreement dated as of November 18, 2015 (the “Original
Agreement”);

 

WHEREAS, the Company,
Broadband Advisory and Broadband Capital are parties to that certain Amended and Restated Management Services Agreement dated as
of July 1, 2016 (the “A&R Agreement”);

 

WHEREAS, Broadband
Advisory provided the consulting services described in the Original Agreement to the Company from the date of the Original Agreement
until the date of the A&R Agreement, and Broadband Capital has provided such consulting services in Broadband Advisory’s
place since the date of the A&R Agreement, and desires to continue providing such consulting services from the date hereof
until the termination of this Agreement;

 

WHEREAS, the Company,
Broadband Advisory and Broadband Capital desire to amend and restate the A&R Agreement to, among other things, provide for
the allocation of Common Stock to Broadband Advisory in exchange for prior advisory services;

 

WHEREAS, members of
Broadband Capital are experienced in corporate finance, strategic corporate planning, management recruiting services, and other
management skills and advisory services;

 

WHEREAS, the Company
has required and will continue to require the special skills and management advisory services (collectively, “Advisory
Services”) of Broadband in connection with its business operations and the execution of its strategic plan following
the consummation of the transactions contemplated by that certain Series A Preferred Stock Purchase Agreement dated as of November
18, 2015 (the “Original Series A Agreement”) and by that certain 2016 Series A Preferred Stock Purchase Agreement
dated as of July 1, 2016 (the “2016 Series A Agreement”);

 

WHEREAS, the Board
of Directors of the Company has approved an increase in the total number of shares of Series A Preferred Stock that may be issued
and sold under the 2016 Series A Agreement, or on the same terms as specified in the 2016 Series A Agreement, to an aggregate total
of $15,000,000 in shares of Series A Preferred Stock (the $15,000,000 in shares of Series A Preferred Stock are hereinafter referred
to as the “2016 Shares”); and

 

WHEREAS, Broadband
Capital is willing to provide such skills and services to the Company upon the terms set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company, Broadband Advisory and Broadband Capital agree that the A&R Agreement shall
be further amended and restated in its entirety by this Agreement and the parties hereto, intending to be legally bound, hereby
further agree as follows:

 

    1

     

    

 

1.             Services.

 

(a)           Company hereby engages Broadband Capital as a consultant pursuant to the terms of this Agreement and Broadband Capital accepts
such engagement. Broadband Capital hereby agrees that if, during the term of this Agreement, Company reasonably and specifically
requests that Broadband Capital provide the services set forth below, Broadband Capital will provide the following services to
Company and its respective subsidiaries (if any): (a) advice in connection with agreements, contracts, documents and instruments
related to the Company; (b) advice with respect to the development and implementation of strategies for improving the operating,
marketing and financial performance of Company, and other senior management matters related to the business, administration and
policies of Company; and (c) such other services (which may include financial and strategic planning and analysis, consulting services,
and human resources and executive recruitment services) as may from time to time be requested. Broadband Capital shall not have
any obligation to Company as to the method or timing of services rendered hereunder, and Company shall not have any right to dictate
or direct the details of the performance of services by Broadband Capital rendered hereunder. Broadband Capital and Company each
understand and acknowledge that Company or any of its affiliates may from time to time engage one or more investment bankers or
financial advisors to provide services in addition to, but not in lieu of, services provided by Broadband Capital under this Agreement.
Company understands and acknowledges that Broadband Capital’s services are not exclusive and Broadband Capital may render
such services to other Persons (defined below). This Agreement shall in no way prohibit Broadband Capital, Broadband Advisory or
any of their respective affiliates or any of their respective partners (both general and limited), members (both managing and otherwise),
officers, directors, employees, agents or representatives from engaging in other activities, whether or not competitive with any
business of Company or any of its respective affiliates.

 

(b)           In connection with the Advisory Services set forth in Section 1(a) above, the Company agrees to elect and appoint Michael
Rapp and David Kutcher to serve as the Company’s Non-Executive Chairman of the Company’s board of directors and Acting
Chief Financial Officer, respectively. Such individuals shall be entitled to serve in such positions for the duration of this Agreement,
or until the earlier of their death, resignation or removal by a majority of the members of the board of directors and/or, in the
case of Michael Rapp, the requisite stockholders of the Company.

 

2.             Additional Commitments by Broadband. Broadband Advisory (or, provided that Broadband Advisory shall remain primarily
liable for the obligations under this Section 2, its designee(s)) shall purchase shares of Series A Preferred Stock of the Company
(the “Adviser Commitment”) as follows. Capitalized terms used by not defined herein shall have the meanings
ascribed to them in the 2016 Series A Agreement.

 

(a)           Broadband Advisory (or its designee(s)) shall purchase shares of Series A Preferred Stock of the Company in the amount and
on the date specified in, and otherwise pursuant to the terms of, Section 1.4 of the Original Series A Agreement; and

 

    2

     

    

 

(b)           Within 10 days after the earlier of (A) June 30, 2017, or (B) the achievement of the Milestone Events (as defined below),
the Company shall deliver to Broadband Advisory a written notice (the “Milestone Closing Notice”) that an additional
closing (the “Milestone Closing”) will be consummated and specifying the date thereof, which shall be not less
than 15 days and not more than 45 days following the date that the Milestone Closing Notice is delivered. Additionally, at any
time prior to the earliest date on which the Company may deliver a Milestone Closing Notice to Broadband Advisory, Broadband Advisory
may, at its election, deliver to the Company a Milestone Closing Notice that the Milestone Closing will be consummated and specifying
the date thereof, which shall also be not less than 15 days and not more than 45 days following the date that the Milestone Closing
is delivered. At the Milestone Closing, the Company shall sell, and Broadband Advisory and/or its designees (“Milestone
Purchasers”) shall purchase, on the same terms and conditions as those contained in the 2016 Series A Agreement, an aggregate
of $2,000,000 in additional shares (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or similar recapitalization affecting such shares) of Series A Preferred Stock. Each Milestone Purchaser who is not already a party
thereto shall become a party to the Transaction Agreements applicable to the Milestone Closing, by executing and delivering a counterpart
signature page to, or other agreement satisfactory to the Company agreeing to be bound by, each of such Transaction Agreements.
 “Milestone Events” means: (x) receipt by the Company of positive safety and efficacy data in animal testing
in respect of at least one of the Company’s lead product candidates; (y) appointment of three new members of the Company’s
Scientific Advisory Board, mutually agreed by the Board of Directors of the Company and Broadband Capital; and (z) advanced discussions
towards a term sheet with a potential strategic partner, as determined by the Company’s Board of Directors, including the
approval of at least one Broadband Director (as defined in the Voting Agreement).

 

3.             Compensation for Advisory Services. In exchange for the Advisory Services, the Company shall pay Broadband Capital
a cash fee of $20,000 per month (“Cash Fee”), to be paid in advance by the fifth day of each month, effective
as of, and retroactive to, May 1, 2016.

 

4.             Allocation of Common Stock in Exchange for Prior Advisory Services. As additional consideration for (i) the Advisory
Services given on or before the date hereof, and (ii) the Adviser Commitment, the Company shall issue to Broadband Advisory
that number of restricted shares of the Company’s Common Stock (the “Broadband Advisory Shares”) which
shall equal 20.0% of the Company’s outstanding Common Stock on an as-converted, fully diluted basis, assuming that all of
the transactions contemplated by the Original Series A Agreement and Section 2 of this Agreement have been consummated as of the
date of this Agreement, and that all of the 2016 Shares have been issued and sold as of the date of this Agreement, and including
any increases to the authorized option pool and Common Stock issued or issuable to any other parties that are contemplated as of
the date hereof and that are illustrated in the capital structure attached hereto as Exhibit A (which capital structure is inclusive
of the issuance of the Broadband Advisory Shares). Further, should the size of the total investment in Series A Preferred Stock
exceed the number of the 2016 Shares, then the Company will issue to Broadband Advisory such number of additional restricted shares
of the Company’s Common Stock in order for Broadband Advisory to be able to maintain its 20.0% interest. The Company shall
issue the Broadband Advisory Shares to Broadband Advisory in the most tax efficient manner, as determined in Broadband Advisory’s
reasonable discretion. The Company has engaged EisnerAmper LLP to value the Common Stock of the Company, including the Broadband
Advisory Shares, for GAAP and its tax reporting purposes, and such valuation has been completed. The Broadband Advisory Shares
shall be issued to Broadband Advisory on the date of this Agreement; provided, however, that the Broadband Advisory
Shares shall vest as follows:

 

    3

     

    

 

(a)           70.0% of the Broadband Advisory Shares will be fully vested as of the date of this Agreement; and

 

(b)           30.0% of the Broadband Advisory Shares will vest upon the earlier of (A) the consummation of the Milestone Closing
(as such term is defined in the Original Series A Agreement and as defined herein) (including the Adviser Commitment); (B) the
Company entering into an agreement with a strategic investor to provide for a non-dilutive financing of at least $5,000,000; (C)
the closing of the sale of shares of Common Stock of the Company to the public at a price of at least $4.50 per share (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect
to the Common Stock) in a firm-commitment underwritten public offering pursuant to an effective registration statement under the
Securities Act of 1933, as amended (the “Securities Act”); (D) the closing of the sale of shares of capital
stock of the Company in a private placement at a price of at least $4.50 per share (subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization with respect to the Company’s Common Stock);
or (E) a Deemed Liquidation Event (as defined in the Certificate of Incorporation of the Company as in effect as of the date hereof
(the “Charter”)) in which Common Stock of the Company is valued at a price of at least $4.50 per share inclusive
of any earn-outs to the extent then determinable (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Common Stock). An earn-out shall be deemed determinable if the
amount thereof is fixed (in which event the fixed amount shall be used) or if the amount thereof is not fixed but a maximum is
specified (in which event the maximum amount shall be used).

 

(c)           As stated in the first paragraph of Section 4, the aggregate number of Broadband Advisory Shares issuable to Broadband Advisory
assumes that the Company has issued all of the 2016 Shares. Without limitation of Section 4(a), if, on the day immediately prior
to the consummation of a Deemed Liquidation Event or an IPO (as defined below), or the date that it is determined by the Board
of Directors that there will be no additional sales of shares of Series A Preferred Stock by the Company (the “Determination
Date”), the Company has not issued the full amount of the 2016 Shares, then the number of Broadband Advisory Shares (whether
vested or unvested) shall be reduced by that number of Broadband Advisory Shares yielded by the following formula: (i) such initial
number of Broadband Advisory Shares minus (ii) the number of shares as shall equal 20.0% of the Company’s outstanding
Common Stock on an as-converted, fully diluted basis as of the Determination Date; provided that, for purposes of such calculation,
all issuances and reservations of shares of Common Stock (on an as-converted, fully diluted basis) occurring from the date of this
Agreement through the Determination Date that were not otherwise taken into account for purposes of arriving at the initial number
of Broadband Advisory Shares specified above in this Section 4 shall be disregarded and shall not be included in the outstanding
shares. Broadband Advisory shall take such actions as are reasonably requested by the Company to memorialize the forfeiture described
in the preceding sentence, although the failure to take any such action shall not have any effect on the validity of such forfeiture;
provided that, Broadband Advisory may allocate such forfeiture among vested or unvested shares, and among its individual
members, as it deems appropriate.

 

    4

     

    

 

(d)           The Company hereby acknowledges and agrees that Broadband Advisory will file an 83(b) election with respect to some or all
of the Broadband Advisory Shares within 30 days of the date hereof, and that, as of the date hereof, such shares have a fair market
value equal to the fair market value in the EisnerAmper LLP valuation report issued to the Company on or about the date hereof.

 

5.             Reimbursements; Fees Generally.

 

(a)           In addition to the Broadband Advisory Shares and Cash Fee, the Company shall promptly, after delivery to the Company of
documentation in support thereof, reimburse Broadband Advisory and/or Broadband Capital, respectively, for all fees and expenses
incurred respectively thereby in connection with such party’s performance of services hereunder, including but not limited
to any out-of-pocket expenses incurred by Broadband Advisory, Broadband Capital or their respective legal counsel, accountants
and other consultants and advisors in connection with the provision of services hereunder. Such reimbursements are not to exceed
$5,000 in the aggregate without the prior consent of the Company; provided that no such consent shall be required for legal expenses
that the Company has agreed to as of the date hereof, or for reasonable out-of-pocket expenses incurred for travel to and from
meetings of the Board of Directors or other travel required by Broadband Capital or Broadband Advisory or its representatives to
perform such party’s respective obligations and duties hereunder, including reasonable transportation expenses required for
Mr. Kutcher to travel to the Company’s offices. Travel accommodations for Broadband pursuant to this Agreement to any destination
other than Philadelphia, Pennsylvania shall be made in accordance with Broadband’s travel policy.

 

(b)           All fees payable pursuant to this Agreement shall be non-refundable, absolute, irrevocable and unconditional, shall be paid
without offset, defense, claim, deduction or any other claim and irrespective of the level, quality or amount of service provided.

 

6.             Term. This Agreement shall terminate automatically two years from the date hereof unless extended in writing by mutual
agreement of the parties; provided, however, that this Agreement shall automatically terminate upon consummation of a Deemed Liquidation
Event or an IPO. Each of (a) the obligations of Broadband under Sections 2(b) and 7(b) any and all owed and unpaid obligations
of Company under Sections 3, 4 and 5, including but not limited to the vesting of the Broadband Advisory Shares as described in
Section 4(b), and (c) the provisions of Section 11, shall survive any termination of this Agreement to the maximum extent permitted
under applicable law. “IPO” means the initial public offering registered on Form S-1 (or any successor form
under the Securities Act).

 

7.             Non-Disclosure; Inventions and Discoveries.

 

(a)           Non-Disclosure. Each of Broadband Capital and Broadband Advisory acknowledges that, in the course of this Agreement,
such party may obtain knowledge of the Company’s business plans, financial information, products, processes, software, know-how,
trade secrets, formulas, methods, prototypes, discoveries, inventions, customer, contractor and supplier lists, names and positions
of employees and/or other proprietary and/or confidential information (collectively, the “Confidential Information”).
Each of Broadband Capital and Broadband Advisory shall keep the Confidential Information confidential and shall not to disclose
any Confidential Information to any other Person, or use any Confidential Information for any purpose other than in connection
with the performance of consulting services to the Company hereunder or to monitor its investment in the Company. Each of Broadband
Capital and Broadband Advisory also agrees not to disclose any proprietary and/or confidential information of others that the Company
is obligated to maintain in confidence. Notwithstanding the foregoing, Broadband Capital and/or Broadband Advisory may disclose
Confidential Information to its respective employees, principals and agents (collectively its “Representatives”)
who have a need to know the Confidential Information for purposes of this Agreement; provided, however, that each
such Representative (i) is advised of the existence of this Agreement and Broadband Capital’s and Broadband Advisory’s
obligations hereunder, and (ii) is under at least the same restrictions with respect to the use and confidentiality of the Confidential
Information in this Agreement. Each of Broadband Capital and Broadband Advisory shall be liable for any breach of this Agreement
by any of its Representatives.

 

    5

     

    

 

(b)           Work Product. Each of Broadband Capital and Broadband Advisory shall promptly disclose to the Company, with all necessary
detail, all work product, deliverables, developments, know-how and discoveries made, received, conceived, acquired or written by
such party or any of its Representatives, solely or jointly with others, in the course of performing services for the Company or
that are otherwise made through the use of the Company’s time, facilities or materials (the foregoing collectively, the “Work
Product”). Each of Broadband Capital and Broadband Advisory hereby assigns and transfers to the Company all of such party’s
right, title and interest in and to the Work Product, and each of Broadband Capital and Broadband Advisory further agrees that
it shall sign, acknowledge and deliver all such further papers and assignments as may be necessary to vest title thereto in the
Company.

 

(c)           Company Documentation. All information and materials relating to the Company or the Company’s business that
are, at any time, in the possession or under the control of Broadband Capital or Broadband Advisory shall be returned to the Company
upon the termination of this Agreement and at any other time that the Company may request; provided, however, that Broadband may
keep a copy of any such information or materials for its legal files to monitor compliance with this Agreement but subject to the
continued adherence to the confidentiality and non-use obligations hereunder.

 

(d)           Injunctive Relief. Each of Broadband Capital and Broadband Advisory agrees that, in the event of any breach of the
agreements in this Section 7, the Company shall be entitled to injunctive relief and to such other and further relief as may be
proper without the need to post any bond.

 

    6

     

    

 

8.             Information.

 

(a)           Delivery of Financial Statements. The Company shall deliver to Broadband:

 

(i)            as soon as practicable, but in any event within 150 days after the end of each fiscal year of the Company (1) a balance
sheet as of the end of such year, (2) statements of income and of cash flows for such year and (3) a statement of shareholders’
equity as of the end of such year, all such financial statements audited and certified by independent public accountants of regionally
recognized standing selected by the Company;

 

(ii)           as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal
year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of
the end of such fiscal quarter, all prepared in accordance with United States generally accepted accounting principles (“GAAP”)
(except that such financial statements may (1) be subject to normal year-end audit adjustments; and (2) not contain all notes thereto
that may be required in accordance with GAAP);

 

(iii)          such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as
Broadband may from time to time reasonably request; provided, however, that the Company shall not be obligated under
this Section 8(a) to provide information (1) that the Company reasonably determines in good faith to be a trade secret or confidential
information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (2) the disclosure
of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

If, for any period,
the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries.

 

Notwithstanding anything
else in this Section 8(a) to the contrary, the Company may cease providing the information set forth in this Section 8(a) during
the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related
offering; provided that the Company’s covenants under this Section 8(a) shall be reinstated at such time as the Company
is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.

 

(b)           Inspection. The Company shall permit Broadband Capital and Broadband Advisory, at their own expense, to visit and
inspect the Company’s properties; examine its books of account and records (including banking records and statements, and
stockholder lists and contact information); and discuss the Company’s affairs, finances, and accounts with its officers,
during normal business hours of the Company as may be reasonably requested by Broadband Capital or Broadband Advisory; provided,
however, that the Company shall not be obligated pursuant to this Section 8(b) to provide access to any information that
it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel.

 

    7

     

    

 

9.             Indemnity and Liability. Company hereby agrees to indemnify and hold harmless each of Broadband Capital and Broadband
Advisory, their respective affiliates and partners (both general and limited), and their respective members (both managing and
otherwise), managers, fiduciaries, officers, directors, employees, agents and representatives (each such Person being an “Indemnified
Party”) from and against any and all losses, claims, damages and liabilities, whether joint or several, costs and expenses
of any nature (including reasonable attorneys’ fees and disbursements), judgments, fines, settlements and other amounts arising
from any and all claims, demands, actions, suits or proceedings, whether civil, criminal, administrative, arbitral or investigative,
in which an Indemnified Party was involved or may be involved, or threatened to be involved, as a party or otherwise (the “Liabilities”),
related to, arising out of or in connection with the advisory and consulting services contemplated by this Agreement or the engagement
of Broadband Capital and Broadband Advisory (or any of their respective affiliates) pursuant to, and the performance by Broadband
Capital and Broadband Advisory (or any of their respective affiliates) of the services contemplated by, this Agreement, and any
other action taken by an Indemnified Party on behalf of Company, whether or not pending or threatened, and any other action taken
by an Indemnified Party on behalf of Company, whether or not resulting in any liability and whether or not such action, claim,
suit, investigation or proceeding is initiated or brought by Company. Company will reimburse any Indemnified Party for all reasonable
costs and expenses (including reasonable attorneys’ fees and expenses) as they are incurred in connection with investigating,
preparing, pursuing, defending or assisting in the defense of any action, claim, suit, investigation or proceeding for which the
Indemnified Party would be entitled to indemnification under the terms of the previous sentence, or any action or proceeding arising
therefrom, whether or not such Indemnified Party is a party thereto; provided that, subject to the following sentence, Company
shall be entitled to assume the defense thereof at its own expense, with counsel satisfactory to such Indemnified Party in its
reasonable judgment. Any Indemnified Party may, at its own expense, retain separate counsel to participate in such defense, and
in any action, claim, suit, investigation or proceeding in which both Company or one or more of its subsidiaries (if any), on the
one hand, and an Indemnified Party, on the other hand, is, or is reasonably likely to become, a party, such Indemnified Party shall
have the right to employ one separate counsel at the expense of Company and to control its own defense of such action, claim, suit,
investigation or proceeding if, in the reasonable opinion of counsel to such Indemnified Party, a conflict or potential conflict
exists between Company, on the one hand, and such Indemnified Party, on the other hand, that would make such separate representation
advisable. Company will not, without the prior written consent of the applicable Indemnified Party, settle, compromise or consent
to the entry of any judgment in any pending or threatened claim, suit, investigation, action or proceeding relating to the matters
contemplated hereby (if any Indemnified Party is a party thereto or has been threatened to be made a party thereto) unless such
settlement, compromise or consent includes an unconditional release of the applicable Indemnified Party and each other Indemnified
Party from all liability arising or that may arise out of such claim, suit, investigation, action or proceeding. No Indemnified
Party shall settle or compromise any claim that is subject to indemnification hereunder without the consent of Company; provided
that Company is not in breach of its indemnification obligations hereunder. Company will not be liable under the foregoing indemnification
provision with respect to any Indemnified Party to the extent that any loss, claim, damage, liability, cost or expense is determined
by a court, in a final judgment from which no further appeal may be taken, to have resulted primarily from the gross negligence
or willful misconduct by an Indemnified Party. If an Indemnified Party is reimbursed hereunder for any expenses, such reimbursement
of expenses shall be refunded to the extent it is finally judicially determined that the Liabilities in question resulted primarily
from the gross negligence or willful misconduct of such Indemnified Party. For purposes of this Section 9, “gross negligence
or willful misconduct” will be deemed to have been “finally judicially determined” only if so found in a final
non-appealable judgment of a court of competent jurisdiction to such effect. As used herein, the term “Person”
shall be construed in the broadest sense and means and includes a natural person, a partnership, a corporation, an association,
a joint stock company, a limited liability company, a trust, a joint venture, an unincorporated organization and any other entity
and any federal, state, municipal, foreign or other government, governmental department, commission, board, bureau, agency or instrumentality,
or any private or public court or tribunal. Company agrees that if and to the extent that any indemnification sought by any Indemnified
Party pursuant to this Section 9 is unavailable for any reason, then Company agrees to make the maximum contribution to the payment
and satisfaction of each of the Liabilities which is permissible under applicable law. The rights of any Indemnified Party to indemnification
hereunder will be in addition to any other rights any such Person may have under any other agreement or instrument referenced above
or any other agreement or instrument to which such Indemnified Party is or becomes a party or is or otherwise becomes, a beneficiary
or under law or regulations.

 

    8

     

    

 

10.           Disclaimer and Limitation of Liability; Opportunities.

 

(a)           Disclaimer; Standard of Care. Neither Broadband Capital nor Broadband Advisory makes any representations or warranties,
express or implied, in respect of the services to be provided by either such party hereunder. In no event will Broadband Capital
or Broadband Advisory or any of the Indemnified Parties be liable to Company or any of its respective affiliates for any act, alleged
act, omission or alleged omission that does not constitute gross negligence or willful misconduct of Broadband Capital or Broadband
Advisory as is finally judicially determined in accordance with Section 9.

 

(b)           Freedom to Pursue Opportunities. In recognition that Broadband and the Indemnified Parties currently have, and will
in the future have or will consider acquiring, investments (including controlling interests) in numerous companies with respect
to which Broadband or the Indemnified Parties may serve as an advisor, a director or in some other capacity, and in recognition
that Broadband and the Indemnified Parties have myriad duties to various investors and partners, and in anticipation that Company,
on the one hand and Broadband (or one or more affiliates, associated investment funds or portfolio companies, or clients of Broadband),
on the other hand, may engage in the same or similar activities or lines of business and have an interest in the same areas of
corporate opportunities, and in recognition of the benefits to be derived by Company hereunder and in recognition of the difficulties
that may confront any advisor who desires and endeavors fully to satisfy such advisor’s duties in determining the full scope
of such duties in any particular situation, the provisions of this Section 10(b) are set forth to regulate, define and guide the
conduct of certain affairs of Company as they may involve Broadband. Except as Broadband and the Indemnified Parties may otherwise
agree in writing on or after the date hereof:

 

    9

     

    

 

(i)            Broadband and the Indemnified Parties will have the right: (A) to directly or indirectly engage in any business (including,
without limitation, any business activities or lines of business that are the same as or similar to those pursued by, or competitive
with, Company and its respective subsidiaries (if any) or invest, own or deal in securities of any other Person so engaged in any
business, (B) to directly or indirectly do business with any client or customer of Company and its respective subsidiaries (if
any), (C) to take any other action that Broadband believes in good faith is necessary to or appropriate to fulfill its obligations
as described in the first sentence of this Section 10(b), and (D) not to present potential transactions, matters or business opportunities
to Company or any of their subsidiaries (if any), and to pursue, directly or indirectly, any such opportunity for itself, and to
direct any such opportunity to another Person.

 

(ii)           Broadband and the Indemnified Parties will have no duty (contractual or otherwise) to communicate or present any corporate
opportunities to Company or any of its affiliates or to refrain from any actions specified in Section 9(b)(i), and Company, on
its own behalf and on behalf of its affiliates, hereby renounces and waives any right to require Broadband or any of the Indemnified
Parties to act in a manner inconsistent with the provisions of this Section 10(b).

 

(iii)          Broadband and the Indemnified Parties will not be liable to Company or any of its affiliates for breach of any duty (contractual
or otherwise) by reason of any activities or omissions of the types referred to in this Section 10(b) or of any such Person’s
participation therein.

 

(c)           Limitation of Liability. In no event will Broadband or any of the Indemnified Parties be liable to Company or any
of its respective affiliates for any indirect, special, incidental or consequential damages, including, without limitation, lost
profits or savings, whether or not such damages are foreseeable, or for any third party claims (whether based in contract, tort
or otherwise), relating to the services to be provided by Broadband Capital or Broadband Advisory hereunder.

 

11.           Assignment. No party hereto shall have the right to assign this Agreement without the prior consent of the other
parties hereto, provided, however, that the foregoing shall not apply to any assignment by Broadband Advisory to
a designee of its obligation to purchase securities of the Company pursuant to Section 2 hereof as long as it remains primarily
liable for that obligation. Subject to the foregoing, any attempted assignment in violation of this Section 11 is null and void.

 

12.           Amendments and Waivers. No amendment or waiver of any term, provision or condition of this Agreement shall be effective,
unless in writing and executed by Broadband and the Company. No course of dealing of any Person nor any delay or omission in exercising
any right or remedy shall constitute an amendment of this Agreement or a waiver of any right or remedy of any party hereto. No
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall
any waiver on the part of any party of any right, power or privilege, nor any single or partial exercise of any such right, power
or privilege, preclude any further exercise thereof or the exercise of any other such right, power or privilege.

 

    10

     

    

 

13.           Miscellaneous.

 

(a)           Choice of Law. This Agreement will be governed by and construed and enforced in accordance with the laws of the State
of New York without regard to principles of conflicts of law.

 

(b)           Jurisdiction. Each of the parties hereby irrevocably and unconditionally submits, for itself and/or its property,
to the exclusive jurisdiction of any New York state court or federal court of the United States of America sitting in the State
of New York, and any appellate court from any thereof, in any proceeding arising out of or relating to this Agreement or for recognition
or enforcement of any judgment, and each of the parties hereby irrevocably and unconditionally agrees that all claims in respect
of any such proceeding may be heard and determined in any such New York state court or, to the extent permitted by law, in such
federal court. Each of the parties agrees that a final judgment in any such proceeding shall be conclusive and may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by law.

 

(c)           WAIVER OF JURY TRIAL. EACH OF THE PARTIES HEREBY IRREVOCABLY WAVES, TO THE FULLEST EXTENT PERMITTED UNDER APPLICABLE
LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATED TO THIS AGREEMENT OR
ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES ACKNOWLEDGES THAT HE, SHE OR IT AND THE OTHER PARTIES HERETO HAVE
BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS CONTAINED IN THIS SECTION 13(c).

 

14.           Independent Contractor. The parties agree and understand that each of Broadband Capital and Broadband Advisory is
and shall act as an independent contractor in the performance of its duties hereunder. Each of Broadband Capital and Broadband
Advisory is, and in the performance of its duties hereunder will not hold itself out as, an employee, agent or partner of the Company
and shall have no obligation to act on behalf of, or to bind, the Company.

 

15.           Merger/Entire Agreement. This Agreement, together with the Original Series A Agreement and the 2016 Series A Agreement,
constitutes the entire understanding of the parties, and supersedes all prior agreements, understandings, representations and warranties,
both written and oral, among the parties with respect to the subject matter of this Agreement. This Agreement is not intended to
confer upon any Person other than the parties hereto any rights or remedies. This Agreement amends and restates, and supersedes
in its entirety, the A&R Agreement.

 

16.           Notice. All notices, requests, claims, demands and other communications under this Agreement shall be in writing
and shall be delivered personally, by facsimile or other electronic medium (which is confirmed as provided below) or by overnight
courier (providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall
be specified by like notice):

 

    11

     

    

 

If to Company, to:

 

Immunome, Inc.

3001 Market St #140

Philadelphia, PA 19104

Attn: Chief Executive
Officer

 

with a copy (which shall
not constitute notice) to:

 

Duane Morris LLP

30 South 17th Street

Philadelphia, PA 19103

Attn: Kathleen M.
Shay (facsimile (215) 689-4382) and

  Sandra G. Stoneman (facsimile (215) 689-4420)

 

If to Broadband, to:

 

Broadband Capital Partners
LLC

712 Fifth Avenue, 22nd
Floor

New York, NY 10019

Attn: Philip Wagenheim

 

with a copy (which shall
not constitute notice) to:

 

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.

666 Third Avenue

New York, NY 10017

Attn: Samuel
Effron, Esq.

 

Notice given by personal
delivery or overnight courier shall be effective upon actual receipt. Notice given by facsimile or other electronic medium shall
be confirmed by appropriate answer back and shall be effective upon actual receipt if received during the recipient’s normal
business hours, or at the beginning of the recipient’s next business day if not received during the recipient’s normal
business hours. All notices by facsimile or other electronic medium shall be confirmed promptly after transmission in writing by
personal delivery or overnight courier.

 

17.           Severability. Whenever possible, each provision or portion of any provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision or portion of any provision of this Agreement
is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity,
illegality or unenforceability will not affect any other provision or portion of any provision in such jurisdiction, and this Agreement
shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion
of any provision had never been contained herein.

 

    12

     

    

 

18.           Counterparts. This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each of the parties and delivered to the other parties. Each party
may deliver its signed counterpart of this Agreement to the other parties by means of facsimile or any other electronic medium,
and such delivery will have the same legal effect as hand delivery of an originally executed counterpart.

 

19.           Headings. All descriptive headings in this Agreement are inserted for convenience only and shall be disregarded in
construing or applying any provision of this Agreement.

 

20.           Prevailing Party. If any legal action or other proceedings is brought for a breach of this Agreement or any of the
warranties herein, the prevailing party shall be entitled to recover its reasonable attorneys’ fees and other costs incurred
in bringing such action or proceeding, in addition to any other relief to which such party may be entitled.

 

[Remainder of page intentionally
left blank]

 

    13

     

    

 

IN WITNESS WHEREOF,
each of the parties has caused this Agreement to be executed on its behalf as of the date first above written by its officer or
representative thereunto duly authorized.

 

BROADBAND ADVISORY:

 

	BCM ADVISORY PARTNERS
    LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Member	 
	 	 
	 	 
	BROADBAND CAPITAL:	 
	 	 
	BROADBAND CAPITAL PARTNERS
    LLC	 
	 	 
	By:	 /s/ Michael Rapaport	 
	 	Name: Michael Rapaport	 
	 	Title: Co-Managing Partner	 
	 	 
	 	 
	COMPANY:	 
	 	 
	IMMUNOME, INC.	 
	 	 
	By: 	/s/ Michael Widlitz	 
	 	Name: Michael Widlitz	 
	 	Title: Director	 

 

(Signature Page to Second Amended and Restated Management Services Agreement)

 

    

     

    

 

Exhibit A

 

Capital Structure

 

    A-1

     

    

 

AMENDMENT TO SECOND
AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT

 

THIS AMENDMENT TO SECOND
AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT (this “Amendment”) is executed on June 12, 2018, by and among
BCM Advisory Partners LLC, a Delaware limited liability company (“Broadband Advisory”), Broadband Capital Partners
LLC, a Delaware limited liability company (“Broadband Capital”, and, together with Broadband Advisory, “Broadband”),
and Immunome, Inc., a Delaware corporation (the “Company”).

 

Background:

 

Broadband and the Company
are parties to that certain Second Amended and Restated Management Services Agreement dated as of January 17, 2017 (the “Agreement”),
pursuant to which the Company continued to engage Broadband to perform certain management advisory services for the Company. The
parties are entering into this Amendment to amend certain provisions of the Agreement, as set forth below.

 

Terms:

 

NOW, THEREFORE, in consideration
of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.             Amendment
to Section 6. The first sentence of Section 6 is hereby amended and restated in its entirety so as to read as follows:

 

“This Agreement
shall terminate automatically on June 30, 2020 unless extended in writing by mutual agreement of the parties; provided,
however, that this Agreement shall automatically terminate upon consummation of a Deemed Liquidation Event or an IPO.”

 

2.             Effect
of Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants and conditions of the Agreement
shall hereafter continue in full force and effect in accordance with the terms thereof, except to the extent expressly modified,
amended or revised herein; provided, however, that if any term or provision of this Amendment shall conflict with or otherwise
be inconsistent with any term or provision of the Agreement, the terms and provisions of this Amendment shall prevail.

 

3.             Governing
Law. This Amendment will be governed by and construed and enforced in accordance with the laws of the State of New York
without regard to principles of conflicts of law.

 

4.             Counterparts;
Electronic Transmission. This Amendment may be executed in counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the other
parties. Each party may deliver its signed counterpart of this Amendment to the other parties by means of facsimile or any other
electronic medium, and such delivery will have the same legal effect as hand delivery of an originally executed counterpart.

 

(Signature Page Follows)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have caused this Amendment to be duly executed and delivered as of the day and year first above written.

 

BROADBAND
ADVISORY:

 

	BCM ADVISORY PARTNERS LLC	 
	 	 
	By: 	/s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Member	 
	 	 
	 	 
	BROADBAND CAPITAL:	 
	 	 
	BROADBAND CAPITAL PARTNERS
    LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Member	 
	 	 
	 	 
	COMPANY:	 
	 	 
	IMMUNOME, INC.	 
	 	 
	By:	 /s/ Michael Morin	 
	 	Name: Michael Morin	 
	 	Title: CEO	 

 

Signature Page to Amendment to Second Amended and Restated Management Services Agreement

 

    

     

    

 

SECOND AMENDMENT
TO SECOND AMENDED AND RESTATED 

 

MANAGEMENT SERVICES
AGREEMENT

 

THIS SECOND AMENDMENT
TO SECOND AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT (this “Second Amendment”) is executed as of March
3, 2020, by and among BCM Advisory Partners LLC, a Delaware limited liability company (“Broadband Advisory”),
Broadband Capital Partners LLC, a Delaware limited liability company (“Broadband Capital”, and, together with
Broadband Advisory, “Broadband”), and Immunome, Inc., a Delaware corporation (the “Company”).

 

Background:

 

Broadband and the Company
are parties to that certain Second Amended and Restated Management Services Agreement dated as of January 17, 2017 as amended on
June 12, 2018 (the “Agreement”), pursuant to which the Company continued to engage Broadband to perform certain
management advisory services for the Company. The parties are entering into this Second Amendment to amend certain provisions of
the Agreement, as set forth below.

 

Terms:

 

NOW, THEREFORE, in consideration
of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.             Second
Amendment to Section 6. The first sentence of Section 6 is hereby amended and restated in its entirety so as to read
as follows:

 

“This Agreement
shall terminate automatically on June 30, 2021 unless extended in writing by mutual agreement of the parties.”

 

2.             Effect
of Second Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants and conditions of
the Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the extent expressly
modified, amended or revised herein; provided, however, that if any term or provision of this Second Amendment shall conflict with
or otherwise be inconsistent with any term or provision of the Agreement, the terms and provisions of this Second Amendment shall
prevail.

 

3.             Governing
Law. This Second Amendment will be governed by and construed and enforced in accordance with the laws of the State of
New York without regard to principles of conflicts of law.

 

4.             Counterparts;
Electronic Transmission. This Second Amendment may be executed in counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the
other parties. Each party may deliver its signed counterpart of this Second Amendment to the other parties by means of facsimile
or any other electronic medium, and such delivery will have the same legal effect as hand delivery of an originally executed counterpart.

 

    

     

    

 

IN WITNESS WHEREOF, the
parties bate caused this Second Amendment to be duly executed and delivered as of the day and year fast above written.

 

BROADBAND
ADVISORY:

 

	BCM ADVISORY PARTNERS LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Partner	 
	 	 
	 	 
	BROADBAND CAPITAL:	 
	 	 
	BROADBAND CAPITAL PARTNERS
    LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Partner	 
	 	 
	 	 
	COMPANY:	 
	 	 
	IMMUNOME, INC.	 
	 	 
	By: 	/s/ Purnanand Sarma	 
	 	Name: Purnanand Sarma	 
	 	Title: President and CEO	 

 

    

     

    

 

THIRD AMENDMENT
TO SECOND AMENDED AND RESTATED

 

MANAGEMENT SERVICES
AGREEMENT

 

THIS THIRD AMENDMENT TO
SECOND AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT (this “Third Amendment”) is executed as of August
4, 2020, by and among BCM Advisory Partners LLC, a Delaware limited liability company (“Broadband Advisory”),
Broadband Capital Partners LLC, a Delaware limited liability company (“Broadband Capital”, and, together with
Broadband Advisory, “Broadband”), and Immunome, Inc., a Delaware corporation (the “Company”).

 

Background:

 

Broadband and the Company
are parties to that certain Second Amended and Restated Management Services Agreement, dated as of January 17, 2017, as amended
on June 12, 2018 and March 3, 2020 (the “Agreement”), pursuant to which Broadband is engaged to perform certain
management advisory services for the Company. The parties are entering into this Third Amendment to amend certain provisions of
the Agreement, as set forth below.

 

Terms:

 

NOW, THEREFORE, in consideration
of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.             Amendments.

 

1.1           Section
4(b) of the Agreement is hereby amended and restated in its entirety so as to read as follows:

 

“30.0% of
the Broadband Advisory Shares shall vest in full on August 4, 2020. As a result, all Broadband Advisory Shares issued hereunder
are now fully vested.”

 

1.2           Section
4(c) of the Agreement is hereby deleted from the Agreement and Section 4(d) of the Agreement is hereby renumbered as Section 4(c).

 

1.3           The
second sentence of Section 6 is hereby amended and restated in its entirety so as to read as follows:

 

“Each
of (a) the obligations of Broadband under Sections 2(b) and 7; (b) the obligations of Company under Sections 3 and 5 that are then
due and owing; and (c) the provisions of Section 11 shall survive any expiration or sooner termination of this Agreement to the
maximum extent permitted under applicable law.”

 

1.4       The
third sentence of Section 6 is hereby deleted from the Agreement.

 

    1

     

    

 

2.             Effect
of Third Amendment.

 

2.1           The
Stock Subscription Agreement effective as of May 17, 2017 and the Stock Subscription Agreement effective as of January 17, 2017,
each between the Company and Broadband Advisory, are hereby amended so as to give effect to the full vesting of the shares of Common
Stock held by Broadband Advisory.

 

2.2           The
parties acknowledge and agree that all of the terms, provisions, covenants and conditions of the Agreement shall hereafter continue
in full force and effect in accordance with the terms thereof, except to the extent expressly modified, amended or revised herein;
provided, however, that if any term or provision of this Third Amendment shall conflict with or otherwise be inconsistent with
any term or provision of the Agreement, the terms and provisions of this Third Amendment shall prevail.

 

3.             Governing
Law. This Third Amendment will be governed by and construed and enforced in accordance with the laws of the State of
New York without regard to principles of conflicts of law.

 

4.             Counterparts;
Electronic Transmission. This Third Amendment may be executed in counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the
other parties. Each party may deliver its signed counterpart of this Third Amendment to the other parties by means of facsimile
or any other electronic medium, and such delivery will have the same legal effect as hand delivery of an originally executed counterpart.

 

    2

     

    

 

IN WITNESS WHEREOF, the
parties have caused this Third Amendment to be duly executed and delivered as of the day and year first above written.

 

BROADBAND
ADVISORY:

 

	BCM ADVISORY PARTNERS LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Partner	 
	 	 
	 	 
	BROADBAND CAPITAL:	 
	 	 
	BROADBAND CAPITAL PARTNERS
    LLC	 
	 	 
	By:	 /s/ Philip Wagenheim	 
	 	Name: Philip Wagenheim	 
	 	Title: Managing Partner	 
	 	 
	 	 
	COMPANY:	 
	 	 
	IMMUNOME, INC.	 
	 	 
	By: 	/s/ Purnanand Sarma	 
	 	Name: Purnanand Sarma	 
	 	Title: President and CEO	 

 

Signature Page to Third Amendment to Second Amended and Restated Management Services AgreementExhibit 10.20

 

IMMUNOME, INC.

 

SERIES A PREFERRED
STOCK PURCHASE AGREEMENT

 

    

     

    

 

TABLE OF CONTENTS

 

Page

	1.	Purchase and Sale of Preferred Stock	1
	 	1.1   	Authorization of Sale and Issuance of Series A Preferred Stock; Deliveries	1
	 	1.2   	Sale of Shares of Series A Preferred Stock at Initial Closing	1
	 	1.3   	Sale of Shares of Series A Preferred Stock at Additional Closings	2
	 	1.4   	Sale of Shares of Series A Preferred Stock at Milestone Closing	2
	 	1.5   	Defined Terms Used in this Agreement	2
	2.	Representations and Warranties of the Company	4
	 	2.1   	Organization, Corporate Power and Qualification	4
	 	2.2   	Capitalization	4
	 	2.3   	Subsidiaries	6
	 	2.4   	Authorization	6
	 	2.5   	Valid Issuance of Shares	6
	 	2.6   	Governmental Consents and Filings	7
	 	2.7   	Litigation	7
	 	2.8   	Intellectual Property	7
	 	2.9   	Compliance with Other Instruments	8
	 	2.10   	Agreements; Actions	8
	 	2.11   	Certain Transactions	9
	 	2.12   	Rights of Registration and Voting Rights	9
	 	2.13   	Property	10
	 	2.14   	Financial Statements	10
	 	2.15   	Changes	10
	 	2.16   	Employee Matters	11
	 	2.17   	Tax Returns and Payments	12
	 	2.18   	Insurance	13
	 	2.19   	Employee Agreements	13
	 	2.20   	Permits	13
	 	2.21   	Corporate Documents	13
	 	2.22   	Environmental and Safety Laws	13
	 	2.23   	Disclosure	14
	 	2.24   	Qualified Small Business Stock	14
	3.	Representations and Warranties of the Purchasers	14
	 	3.1   	Authorization	14
	 	3.2   	Purchase Entirely for Own Account	14
	 	3.3   	Disclosure of Information	15
	 	3.4   	Restricted Securities	15
	 	3.5   	No Public Market	15
	 	3.6   	Legends	15
	 	3.7   	Accredited Investor	15
	 	3.8   	Investment Risk	16
	 	3.9   	Foreign Investors	16
	 	3.10   	No General Solicitation	16

 

    i

     

    

 

	 	3.11   	Exculpation Among Purchasers	16
	 	3.12   	Residence	16
	 	3.13   	Acknowledgement of BAP Investment	16
	4.	Conditions to the Purchasers’ Obligations at Initial Closing	17
	 	4.1   	Representations and Warranties	17
	 	4.2   	Performance	17
	 	4.3   	Compliance Certificate	17
	 	4.4   	Qualifications	17
	 	4.5   	Opinion of Company Counsel	17
	 	4.6   	Board of Directors	17
	 	4.7  	Indemnification Agreements	17
	 	4.8   	Investor Rights Agreement	17
	 	4.9   	Right of First Refusal and Co-Sale Agreement	17
	 	4.10   	Voting Agreement	17
	 	4.11   	Certificate	18
	 	4.12   	Secretary’s Certificate	18
	 	4.13   	Proceedings and Documents	18
	 	4.14   	Preemptive Rights	18
	 	4.15   	Conversion	18
	5.	Conditions of the Company’s Obligations at Closing	18
	 	5.1   	Representations and Warranties	18
	 	5.2   	Performance	18
	 	5.3   	Qualifications	18
	 	5.4   	Investor Rights Agreement	18
	 	5.5   	Right of First Refusal and Co-Sale Agreement	18
	 	5.6   	Voting Agreement	19
	6.	Miscellaneous	19
	 	6.1   	Survival of Warranties	19
	 	6.2   	Successors and Assigns	19
	 	6.3   	Governing Law	19
	 	6.4   	Counterparts	19
	 	6.5   	Conversion to Delaware Corporation	19
	 	6.6   	Titles and Subtitles	19
	 	6.7   	Notices	19
	 	6.8   	No Finder’s Fees	20
	 	6.9   	Attorneys’ Fees	20
	 	6.10   	Amendments and Waivers	20
	 	6.11   	Severability	20
	 	6.12   	Delays or Omissions	20
	 	6.13   	Entire Agreement	20
	 	6.14   	WAIVER OF JURY TRIAL	21
	 	6.15   	Arbitration	21
	 	6.16   	No Commitment for Additional Financing	21

 

    ii

     

    

 

	Exhibit A -	FORM OF SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION
	 	 
	Exhibit B -	DISCLOSURE SCHEDULE
	 	 
	Exhibit C -	FORM OF INDEMNIFICATION AGREEMENT
	 	 
	Exhibit D -	FORM OF INVESTOR RIGHTS AGREEMENT
	 	 
	Exhibit E -	FORM OF RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT
	 	 
	Exhibit F -	FORM OF VOTING AGREEMENT
	 	 
	Exhibit G -	FORM OF LEGAL OPINION OF DUANE MORRIS LLP

 

    iii

     

    

 

SERIES A PREFERRED
STOCK PURCHASE AGREEMENT

 

THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT
(this “Agreement”), is made as of the 18th day of November, 2015 by and among Immunome, Inc., a Pennsylvania
corporation (the “Company”), the investors signing counterpart signature pages hereto (each a “Purchaser”
and together the “Purchasers”).

 

For good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

1.            
Purchase and Sale of Preferred Stock.

 

1.1             
Authorization of Sale and Issuance of Series A Preferred Stock; Deliveries.

 

(a)              
The Company shall adopt and file with the Secretary of State of the State of Pennsylvania on or before the date of the Initial
Closing (as defined below) the Second Amended and Restated Articles of Incorporation of the Company in the form of Exhibit A
attached to this Agreement (the “Certificate”).

 

(b)              
Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the applicable Closing (as defined
below) and the Company agrees to sell and issue to each Purchaser at that Closing, that number of shares of Series A Preferred
Stock, $0.0001 par value per share (the “Series A Preferred Stock”), required to be purchased by such Purchaser
pursuant to this Agreement, at a purchase price of $1.50 per share (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or similar recapitalization affecting such shares, the “Purchase Price”).
The shares of Series A Preferred Stock issued and sold to the Purchasers pursuant to this Agreement (including the Initial Closing
Shares, the Additional Shares and the Milestone Shares (as such terms are defined below)) shall be referred to in this Agreement
as the “Shares.”

 

(c)              
Each closing of the purchase and sale of Shares pursuant to this Agreement (each, a “Closing”) shall
take place remotely via the exchange of documents and signatures at 10:00 a.m. on the date of the applicable Closing or at such
place or time as shall be mutually agreed upon among the Company and each Purchaser. At each Closing, the Company shall deliver
to each Purchaser a certificate representing the Shares being purchased by such Purchaser at such Closing against payment of the
aggregate Purchase Price therefor by check payable to the Company, by wire transfer to a bank account designated by the Company.

 

1.2             
Sale of Shares of Series A Preferred Stock at Initial Closing. At a Closing to take place on the date of this Agreement
(the “Initial Closing”), each Purchaser shall purchase from the Company, and the Company shall sell and issue
to each Purchaser, that number of shares of Series A Preferred Stock (the “Initial Closing Shares”), set forth
under such Purchaser’s name on such Purchaser’s counterpart signature page hereto.

 

    1

     

    

 

1.3             
Sale of Shares of Series A Preferred Stock at Additional Closings. At one or more Closings to occur on or prior to December
15, 2015, the Company may sell, on the same terms and conditions as those contained in this Agreement, additional Shares in an
aggregate amount equal to $5,000,000 in Shares less the number of Shares issued and sold at the Initial Closing (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or similar recapitalization affecting such shares) (the
 “Additional Shares”), to one or more purchasers reasonably acceptable to the Board of Directors of the Company
(the “Additional Purchasers”) (it is hereby acknowledged that holders of convertible promissory notes being
converted on the date hereof purchasing in the aggregate up to $166,000 in Shares are reasonably acceptable); provided, that: (a)
each Additional Purchaser who is not already a party thereto shall become a party to the Transaction Agreements (as defined below),
by executing and delivering a counterpart signature page to, or other agreement satisfactory to the Company agreeing to be bound
by, each of the Transaction Agreements; and (b) at a Closing to be completed on December 15, 2015, BCM Advisory Partners, LLC (“BAP”)
and/or its designees reasonably acceptable to the Board of Directors of the Company shall purchase that number of Additional Shares
equal to the number of Additional Shares that were not purchased, or are not on that date being purchased, by other Additional
Purchasers.

 

1.4             
Sale of Shares of Series A Preferred Stock at Milestone Closing. Within 10 days after achievement of the Milestone Events
(as defined below), the Company shall deliver to BAP and the Purchasers a written notice (the “Milestone Closing Notice”)
that an additional Closing pursuant to this Section 1.4 (the “Milestone Closing”) will be consummated
and specifying the date thereof, which shall be not less than 15 days and not more than 45 days following the date that the Milestone
Closing Notice is delivered. At the Milestone Closing, the Company shall sell, on the same terms and conditions as those contained
in this Agreement, an aggregate of $3,500,000 in additional shares (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or similar recapitalization affecting such shares) of Series A Preferred Stock (the “Milestone
Shares”), to one or more purchasers (“Milestone Purchasers”). The Milestone Shares will be allocated
among the Milestone Purchasers as follows: (a) each existing Purchaser will have the right to purchase up to that portion of $2,500,000
in Milestone Shares determined based upon each such Purchaser’s pro rata ownership of the Shares held by all Purchasers,
with an oversubscription right for fully participating Purchasers; (b) Broadband Capital Management, LLC shall allocate any remaining
Milestone Shares among any other purchaser(s); and (c) BAP and/or its designees will purchase $1,000,000 in Milestone Shares plus
any Milestone Shares that remain unallocated after the application of clauses (a) and (b). Each Milestone Purchaser who is not
already a party thereto shall become a party to the Transaction Agreements, by executing and delivering a counterpart signature
page to, or other agreement satisfactory to the Company agreeing to be bound by, each of the Transaction Agreements.

 

1.5             
Defined Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement
shall be construed to have the meanings set forth or referenced below.

 

(a)              
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing
member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person.

 

    2

     

    

 

(b)              
“Code” means the Internal Revenue Code of 1986, as amended.

 

(c)              
“Company Covered Person” means, with respect to the Company as an “issuer” for purposes of
Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

(d)              
“Company Intellectual Property” means all patents, patent applications, trademarks, trademark applications,
service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary
rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments
of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases as are necessary to the Company
in the conduct of the Company’s business as now conducted and as presently proposed to be conducted.

 

(e)              
“Indemnification Agreement” means the agreement between the Company and the Purchaser Affiliates designated
by any Purchaser entitled to designate a member of the Board of Directors pursuant to the Voting Agreement, dated as of the date
of the Initial Closing, in the form of Exhibit C attached to this Agreement.

 

(f)               
“Investor Rights Agreement” means the agreement among the Company and the Purchasers and certain other
stockholders of the Company dated as of the date of the Initial Closing, in the form of Exhibit D attached to this Agreement.

 

(g)              
“Key Person” means any executive-level employee or independent contractor (including division director
and vice president-level positions, if any) as well as any employee or independent contractor who either alone or in concert with
others develops, invents, programs or designs any Company Intellectual Property.

 

(h)              
“Knowledge” including the phrase “to the Company’s knowledge” shall mean the actual
knowledge after reasonable investigation of Scott Dessain and, for the period of time beginning October 1, 2013, Jane Hollingsworth
and Joel Sussman.

 

(i)                
“Material Adverse Effect” means a material adverse effect on the business, assets (including intangible
assets), liabilities, financial condition, property, prospects or results of operations of the Company.

 

(j)                
“Milestone Events” means: (i) receipt by the Company of positive safety and efficacy data in animal testing
in respect of at least one of the Company’s lead product candidates; (ii) appointment of three new members of the Company’s
Scientific Advisory Board, mutually agreed by the Board of Directors of the Company and BAP; and (iii) advanced discussions towards
a term sheet with a potential strategic partner, as determined by the Company’s Board of Directors, including the approval
of at least one Broadband Director (as defined in the Voting Agreement).

 

(k)              
“Person” means any individual, corporation, partnership, trust, limited liability company, association
or other entity.

 

    3

     

    

 

(l)               
“Purchaser” means each of the Purchasers who is initially a party and any Additional Purchaser who becomes
a party to this Agreement at a subsequent Closing under Section 1.2(b).

 

(m)             
“Right of First Refusal and Co-Sale Agreement” means the agreement among the Company, the Purchasers
and certain other stockholders of the Company, dated as of the date of the Initial Closing, in the form of Exhibit E attached
to this Agreement.

 

(n)              
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.

 

(o)              
“Shares” means the shares of Series A Preferred Stock issued at the Initial Closing, any Additional Shares
issued at a subsequent Closing under Section 1.3 and any Milestone Shares issued at a Milestone Closing under Section
1.4.

 

(p)              
“Transaction Agreements” means this Agreement, the Investor Rights Agreement, the Right of First Refusal
and Co-Sale Agreement and the Voting Agreement.

 

(q)              
“Voting Agreement” means the agreement among the Company, the Purchasers and certain other stockholders
of the Company, dated as of the date of the Initial Closing, in the form of Exhibit F attached to this Agreement.

 

2.            
Representations and Warranties of the Company. The Company hereby represents and warrants to each Purchaser
that, except as set forth on the Disclosure Schedule attached as Exhibit B to this Agreement, which exceptions shall be
deemed to be part of the representations and warranties made hereunder, the following representations are true and complete as
of the date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding
to the numbered and lettered sections and subsections contained in this Section 2, and the disclosures in any section or
subsection of the Disclosure Schedule shall qualify other sections and subsections in this Section 2 only to the extent
it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.

 

2.1             
Organization, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and subsisting
under the laws of the Commonwealth of Pennsylvania and has all requisite corporate power and authority to carry on its business
as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing
as a foreign corporation in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

2.2             
Capitalization.

 

(a)              
The authorized capital of the Company consists, immediately prior to the Initial Closing, of:

 

(i)              
20,000,000 shares of common stock, $0.0001 par value per share (the “Common Stock”). All of the outstanding
shares of Common Stock have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable
federal and state securities laws. The Company holds no Common Stock in its treasury.

 

    4

     

    

 

(ii)             
9,653,200 shares of preferred stock (the “Preferred Stock”), all of which have been designated Series
A Preferred Stock, none of which are issued and outstanding immediately prior to the Initial Closing. The rights, privileges and
preferences of the Preferred Stock are as stated in the Certificate and as provided by the Pennsylvania Business Corporation Law.
The Company holds no Preferred Stock in its treasury.

 

(b)              
The Company has reserved 1,981,508 shares of Common Stock for issuance to officers, directors, employees and consultants
of the Company pursuant to its Amended and Restated 2008 Equity Incentive Plan duly adopted by the Board of Directors and approved
by the Company stockholders (the “Stock Plan”). The Company has made available to the Purchasers or their counsel
complete and accurate copies of the Stock Plan and forms of agreements used thereunder.

 

(c)              
Section 2.2(c) of the Disclosure Schedule sets forth the capitalization of the Company immediately following the Initial
Closing including the number of shares of the following: (i) issued and outstanding Common Stock, including, with respect to restricted
Common Stock, vesting schedule and repurchase price; (ii) granted stock options, including vesting schedule and exercise price;
(iii) restricted stock grants, including vesting (or forfeiture) schedule and purchase price; (iv) shares of Common Stock reserved
for future award grants under the Stock Plan; (v) each series of Preferred Stock and (vi) warrants or stock purchase rights, if
any. Except for: (A) the conversion privileges of the Shares to be issued under this Agreement; (B) the rights provided in Section
4 of the Investor Rights Agreement and (C) the securities and rights described in Section 2.2(a)(ii) and Section 2.2(c)
of the Disclosure Schedule, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights
of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of
Common Stock or Series A Preferred Stock, or any securities convertible into or exchangeable for shares of Common Stock or Series
A Preferred Stock. All outstanding shares of the Company’s Common Stock and all shares of the Company’s Common Stock
underlying outstanding options are subject to (1) a right of first refusal in favor of the Company upon any proposed transfer (other
than transfers for estate planning purposes) and (2) a lock-up or market standoff agreement of not less than 180 days following
the Company’s initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission
under the Securities Act.

 

(d)              
None of the Company’s stock purchase agreements or stock option documents contains a provision for acceleration of
vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding
upon the occurrence of any event or combination of events, including without limitation in the case where the Company’s Stock
Plan is not assumed in an acquisition. The Company has never adjusted or amended the exercise price of any stock options previously
awarded, whether through amendment, cancellation, replacement grant, repricing or any other means. Except as set forth in the Certificate,
the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock.

 

    5

     

    

 

(e)              
The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by this Agreement.

 

2.3             
Subsidiaries. The Company does not currently own or control, directly or indirectly, any interest in any other corporation,
partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant
in any joint venture, partnership or similar arrangement.

 

2.4             
Authorization. All corporate action required to be taken by the Company’s Board of Directors and stockholders
in order to authorize the Company to enter into the Transaction Agreements, and to issue the Shares at each Closing and the Common
Stock issuable upon conversion of the Shares, has been taken or will be taken prior to that Closing. All action on the part of
the officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations
of the Company under the Transaction Agreements to be performed as of the applicable Closing, and the issuance and delivery of
the Shares has been taken or will be taken prior to that Closing. The Transaction Agreements, when executed and delivered by the
Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with
their respective terms except: (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
or other laws of general application relating to or affecting the enforcement of creditors’ rights generally; (b) as limited
by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies or (c) to the extent
the indemnification provisions contained in the Investor Rights Agreement and the Indemnification Agreements may be limited by
applicable federal or state securities laws.

 

2.5             
Valid Issuance of Shares.

 

(a)              
The Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement,
will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under
the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser.
Assuming the accuracy of the representations of the Purchasers in Section 3 and subject to the filings described in Section
2.5(b)(ii), the Shares will be issued in compliance with all applicable federal and state securities laws. The Common Stock
issuable upon conversion of the Shares has been duly reserved for issuance, and upon issuance in accordance with the terms of the
Certificate, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions
on transfer under the Transaction Agreements, applicable federal and state securities laws and liens or encumbrances created by
or imposed by a Purchaser. Based in part upon the representations of the Purchasers in Section 3, and subject to Section
2.5(b), the Common Stock issuable upon conversion of the Shares will be issued in compliance with all applicable federal and
state securities laws.

 

(b)              
No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification
Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person, except for a Disqualification
Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable.

 

    6

     

    

 

2.6             
Governmental Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section
3, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority is required on the part of the Company in connection with the consummation of
the transactions contemplated by this Agreement, except for: (a) the filing of the Certificate, which will have been filed as of
the Initial Closing and (b) filings pursuant to Regulation D of the Securities Act, and applicable state securities laws, which
have been made or will be made in a timely manner.

 

2.7             
Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or
to the Company’s knowledge, currently threatened in writing against the Company or to the Company’s knowledge any officer,
director or Key Person of the Company, or: (a) that questions the validity of the Transaction Agreements or the right of the Company
to enter into them, or to consummate the transactions contemplated by the Transaction Agreements; or (b) to the Company’s
knowledge, that would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither
the Company nor, to the Company’s knowledge, any of its officers, directors or Key Persons is a party or is named as subject
to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the
case of officers, directors or Key Persons, such as would affect the Company). There is no action, suit, proceeding or investigation
by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings
or investigations pending or threatened in writing (or any basis therefor known to the Company) involving the prior employment
of any of the Company’s employees, their services provided in connection with the Company’s business, any information
or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.

 

2.8             
Intellectual Property. The Company owns or possesses or believes it can acquire on commercially reasonable terms sufficient
legal rights to all Company Intellectual Property without, to the Company’s knowledge, any conflict with, or infringement
of, the rights of others. To the Company’s knowledge, no product or service marketed or sold (or proposed to be marketed
or sold) by the Company violates or will violate any license or infringes or will infringe any intellectual property rights of
any other party. Other than with respect to commercially available software products under standard end-user object code license
agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind
relating to the Company Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of
any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information,
proprietary rights and processes of any other Person. The Company has not received any communications alleging that the Company
has violated, or by conducting its business, would violate any of the patents, trademarks, service marks, tradenames, copyrights,
trade secrets, mask works or other proprietary rights or processes of any other Person. The Company has obtained and possesses
valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that
it owns or leases or that it has otherwise provided to its employees for their use in connection with the Company’s business.
To the Company’s knowledge, it will not be necessary to use any inventions of any of its employees or consultants (or Persons
it currently intends to hire) made prior to their employment by the Company. Each employee and consultant has assigned to the Company
all intellectual property rights he or she owns that are related to the Company’s business as now conducted and as presently
proposed to be conducted. Section 2.8 of the Disclosure Schedule lists all registered Company Intellectual Property or Company
Intellectual Property that is the subject of a filed application. The Company has not embedded any open source, copyleft or community
source code in any of its products generally available or in development, including but not limited to any libraries or code licensed
under any General Public License, Lesser General Public License or similar license arrangement. For purposes of this Section
2.8, the Company shall be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right
or would be found to be on notice of such patent right as determined by reference to United States patent laws.

 

    7

     

    

 

2.9             
Compliance with Other Instruments. The Company is not in violation or default: (a) of any provisions of the Certificate
or its Bylaws; (b) of any instrument, judgment, order, writ or decree; (c) under any note, indenture or mortgage; (d) under any
lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed on the
Disclosure Schedule; or (e) to its knowledge, of any provision of federal or state statute, rule or regulation of any domestic
or foreign governmental authority applicable to the Company, the violation of which would have a Material Adverse Effect. The execution,
delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction
Agreements will not result in any such violation or be in conflict with or constitute, with or without the passage of time and
giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement;
or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension,
revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company.

 

2.10           
Agreements; Actions.

 

(a)              
Except for the Transaction Agreements, there are no agreements, understandings, instruments, contracts or proposed transactions
to which the Company is a party or by which it is bound that involve: (i) obligations of, or payments to, the Company in excess
of $50,000; (ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company
that is material to the Company; (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products
to any other Person that limit the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell
its products or (iv) indemnification by the Company with respect to infringements of proprietary rights.

 

(b)              
The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class
or series of its capital stock. The Company: (i) does not have outstanding any indebtedness for money borrowed or any other liability
in excess of $50,000 individually or in excess of $100,000 in the aggregate; (ii) has not made any loans or advances to any Person,
other than ordinary advances for expenses incurred by service providers of the Company in connection with such services and (iii)
has not sold, exchanged or otherwise disposed of any of its material assets or rights, other than dispositions in the ordinary
course of business. For the purposes of (a) and (b) of this Section 2.10, all indebtedness, agreements, instruments and
contracts involving the same Person (including Persons the Company has reason to believe are affiliated with each other) shall
be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection.

 

    8

     

    

 

(c)              
The Company is not a guarantor or indemnitor of any indebtedness of any other Person.

 

(d)              
The Company has not engaged in the past three months in any discussions with any representative of any Person regarding
(i) a sale or exclusive license of all or substantially all of the Company’s assets or (ii) any merger, consolidation or
other business combination transaction of the Company with or into another Person.

 

2.11           
Certain Transactions.

 

(a)              
Other than: (i) standard employee benefits generally made available to all employees; (ii) standard director and officer
indemnification agreements approved by the Board of Directors; (iii) the purchase of shares of the Company’s capital stock
and the issuance of options to purchase shares of the Company’s Common Stock, in each instance, approved in the written minutes
of the Board of Directors or written consents in lieu thereof (previously made available to the Purchasers or their counsel) or
(iv) the transactions contemplated by the Transaction Agreements, there are no agreements between the Company and any of its officers,
directors, consultants or Key Persons or, to the Company’s knowledge, any Affiliate thereof.

 

(b)              
The Company is not indebted, directly or indirectly, to any of its directors, officers or employees or to their respective
spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses
incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally
available to all employees. None of the Company’s directors, officers or employees, or, to the Company’s knowledge,
any members of their immediate families, or any Affiliate of the foregoing are indebted to the Company or, to the Company’s
knowledge, have any: (i) direct or indirect ownership interest in any firm or corporation that is an Affiliate of the Company or
with which the Company has a material business relationship, or any firm or corporation which competes with the Company except
that directors, officers, employees or stockholders of the Company may own stock in (but not exceeding 5% of the outstanding capital
stock of publicly traded companies that may compete with the Company or (ii) personal direct or indirect financial interest in
any material contract with the Company.

 

2.12         
Rights of Registration and Voting Rights. Except as provided in the Investor Rights Agreement, the Company is not under
any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon
exercise or conversion of its currently outstanding securities. To the Company’s knowledge, except as contemplated in the
Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of
the Company.

 

    9

     

    

 

2.13           
Property. The property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens,
loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances
and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such
property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and, to its
knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property
or assets. The Company does not own any real property.

 

2.14           
Financial Statements. Copies of the Company’s unaudited financial statements (including balance sheet, income
statement and statement of cash flows) for the fiscal year ended December 31, 2014 and for the eight-month period ended August
31, 2015 (collectively, the “Financial Statements”) are attached as Section 2.14 of the Disclosure Schedule.
The Financial Statements have been prepared in accordance with generally accepted accounting principles (“GAAP”)
applied on a consistent basis throughout the periods indicated. The Financial Statements fairly present in all material respects
the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject in
the case of the interim Financial Statements to normal year-end audit adjustments. Except as set forth in the Financial Statements,
the Company has no material liabilities or obligations, contingent or otherwise, other than: (a) liabilities incurred in the ordinary
course of business subsequent to August 31, 2015; (b) obligations under contracts and commitments incurred in the ordinary course
of business and (c) liabilities and obligations of a type or nature not required under GAAP to be reflected in the Financial Statements,
which, in all such cases, individually and in the aggregate would not have a Material Adverse Effect. The Company maintains and
will continue to maintain a standard system of accounting established and administered in accordance with GAAP.

 

2.15           
Changes. Since August 31, 2015, there has not been:

 

(a)              
any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the
Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse
Effect;

 

(b)              
any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 

(c)              
any waiver or compromise by the Company of a valuable right or of a material debt owed to it;

 

(d)              
any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in
the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;

 

(e)              
any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;

 

(f)               
any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

 

(g)              
any resignation or termination of employment of any officer or Key Person of the Company;

 

    10

     

    

 

(h)              
any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material
properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and
do not materially impair the Company’s ownership or use of such property or assets;

 

(i)               
any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members
of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

 

(j)                
any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock,
or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;

 

(k)              
any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material
Adverse Effect;

 

(l)               
receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;

 

(m)             
to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy
or the Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or

 

(n)              
any arrangement or commitment by the Company to do any of the things described in this Section 2.15.

 

2.16           
Employee Matters.

 

(a)              
Section 2.16(a)(i) of the Disclosure Schedule lists the current employees of the Company and Section 2.16(a)(ii) of the
Disclosure Schedule lists the current independent contractors of the Company whose services are material to the Company’s
business.

 

(b)              
To the Company’s knowledge, none of its employees is obligated under any contract (including licenses, covenants or
commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency,
that would materially interfere with such employee’s ability to promote the interest of the Company or that would conflict
with the Company’s business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the
Company’s business by the employees of the Company, nor the conduct of the Company’s business as now conducted and
as presently proposed to be conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms,
conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee
is now obligated.

 

(c)              
The Company is not delinquent in payments to any of its employees, consultants, or independent contractors for any wages,
salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required
to be reimbursed to such employees, consultants or independent contractors. The Company has complied in all material respects with
all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related
to wages, hours, worker classification and collective bargaining. The Company has withheld and paid to the appropriate governmental
entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of
the Company and is not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing.

 

    11

     

    

 

(d)              
To the Company’s knowledge, no Key Person intends to terminate employment with the Company or is otherwise likely
to become unavailable to continue as a Key Person, nor does the Company have a present intention to terminate the employment of
any of the foregoing. The employment of each employee of the Company is terminable at the will of the Company. Except as set forth
in Section 2.16(g) of the Disclosure Schedule or as required by law, upon termination of the employment of any such employees,
no severance or other payments will become due. Except as set forth in Section 2.16(g) of the Disclosure Schedule, the Company
has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination
of employment services.

 

(e)              
The Company has not made any representations regarding the grant of equity incentives to any officer, employee, director
or consultant that are inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s
Board of Directors or a written consent in lieu thereof.

 

(f)               
Each former Key Person whose employment was terminated by the Company has entered into an agreement with the Company providing
for the full release of any claims against the Company or any related party arising out of such employment.

 

(g)              
Section 2.16(g) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by
the Company, or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security
Act of 1974, as amended (“ERISA”). The Company has made all required contributions and has no liability to any
such employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA,
and has complied in all material respects with all applicable laws for any such employee benefit plan.

 

(h)              
The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any written or
oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the
knowledge of the Company, has sought to represent any of the employees, representatives or agents of the Company. There is no strike
or other labor dispute involving the Company pending, or to the Company’s knowledge, threatened, which could have a Material
Adverse Effect, nor is the Company aware of any labor organization activity involving its employees.

 

2.17           
Tax Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the Company
which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company
which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by
any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state,
county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable statutes
of limitations with respect to taxes for any year.

 

    12

     

    

 

2.18           
Insurance. The Company has in full force and effect fire and casualty insurance policies with extended coverage, sufficient
in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed.

 

2.19           
Employee Agreements. Each current and former employee, consultant and officer of the Company has executed an agreement
with the Company regarding confidentiality and proprietary information substantially in the form or forms made available to the
Purchasers or their counsel (the “Confidential Information Agreements”). No current or former Key Person has
excluded works or inventions from his or her assignment of inventions pursuant to such Key Person’s Confidential Information
Agreement. Each current and, to the knowledge of the Company, former Key Person has executed non-competition and non-solicitation
agreement appropriate for their positions with the Company. The Company does not know that any of its Key Persons is in violation
of any agreement covered by this Section 2.19.

 

2.20           
Permits. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its
business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any
material respect under any of such franchises, permits, licenses or other similar authority.

 

2.21           
Corporate Documents. The Certificate and the Bylaws of the Company are in the form made available to the Purchasers
or their counsel. The copy of the minute books of the Company made available to the Purchasers or their counsel contains minutes
of all meetings of directors and stockholders and all actions by written consent without a meeting by the directors and stockholders
since the date of incorporation and accurately reflects in all material respects all actions by the directors (and any committee
of directors) and stockholders with respect to all transactions referred to in such minutes.

 

2.22           
Environmental and Safety Laws. Except as could not reasonably be expected to have a Material Adverse Effect: (a) the
Company is and has been in compliance with all Environmental Laws; (b) there has been no release or to the Company’s knowledge
threatened release of any pollutant, contaminant or toxic or hazardous material, substance or waste or petroleum or any fraction
thereof (each a “Hazardous Substance”), on, upon, into or from any site currently or heretofore owned, leased
or otherwise used by the Company; (c) there have been no Hazardous Substances generated by the Company that have been disposed
of or come to rest at any site that has been included in any published U.S. federal, state or local “superfund” site
list or any other similar list of hazardous or toxic waste sites published by any governmental authority in the United States and
(d) there are no underground storage tanks located on, no polychlorinated biphenyls (“PCBs”) or PCB-containing
equipment used or stored on, and no hazardous waste as defined by the Resource Conservation and Recovery Act, as amended, stored
on, any site owned or operated by the Company, except for the storage of hazardous waste in compliance with Environmental Laws.
The Company has made available to the Purchasers or their counsel true and complete copies of all material environmental records,
reports, notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies and environmental
studies or assessments. For purposes of this Section 2.22, “Environmental Laws” means any law, regulation,
or other applicable requirement relating to (i) releases or threatened release of Hazardous Substance; (ii) pollution or protection
of employee health or safety, public health or the environment or (iii) the manufacture, handling, transport, use, treatment, storage,
or disposal of Hazardous Substances.

 

    13

     

    

 

2.23           
Disclosure. No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure
Schedule, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material
fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in
light of the circumstances under which they were made.

 

2.24           
Qualified Small Business Stock. As of and immediately following the Initial Closing: (a) the Company will be an eligible
corporation as defined in Code Section 1202(e)(4); (b) the Company will not have made purchases of its own stock described in Code
Section 1202(c)(3)(B) during the one year period preceding the Initial Closing, except for purchases that are disregarded for such
purposes under Treasury Regulation Section 1.1202-2; and (c) the Company’s aggregate gross assets, as defined by Code Section
1202(d)(2), at no time between its incorporation and through the Initial Closing have exceeded $50,000,000, taking into account
the assets of any corporations required to be aggregated with the Company in accordance with Code Section 1202(d)(3); provided,
however, that in no event shall the Company be liable to the Purchasers or any other party for any damages arising from any subsequently
proven or identified error in the Company’s determination with respect to the applicability or interpretation of Code Section
1202, unless such determination shall have been given by the Company in a manner either grossly negligent or fraudulent.

 

3.            
Representations and Warranties of the Purchasers. Each Purchaser hereby represents and warrants to the
Company as to that Purchaser, severally and not jointly, that:

 

3.1             
Authorization. The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction
Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding
obligations of the Purchaser, enforceable in accordance with their terms, except: (a) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’
rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies; or (b) to the extent the indemnification provisions contained in the Investor Rights Agreement may be limited by applicable
federal or state securities laws.

 

3.2             
Purchase Entirely for Own Account. The Shares to be acquired by the Purchaser will be acquired for investment for the
Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof,
and that the Purchaser has no present intention of selling, granting any participation in or otherwise distributing the same. By
executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking,
agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with
respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Shares.

 

    14

     

    

 

 

3.3             
Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management,
financial affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an
opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the representations and
warranties of the Company in Section 2 or the right of the Purchasers to rely thereon.

 

3.4             
Restricted Securities. The Purchaser understands that the Shares have not been, and will not be, registered under the
Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed
herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state
securities laws and that, pursuant to these laws, the Purchaser must hold the Shares indefinitely unless they are registered with
the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification
requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Shares, or
the Common Stock into which it may be converted, for resale except as set forth in the Investor Rights Agreement. The Purchaser
further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to
the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able
to satisfy.

 

3.5             
No Public Market. The Purchaser understands that no public market now exists for the Shares, and that the Company has
made no assurances that a public market will ever exist for the Shares.

 

3.6             
Legends. The Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares,
may be notated with one or all of the following legends:

 

(a)              
“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO
SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933”;

 

(b)              
Any legend set forth in, or required by, the other Transaction Agreements; and

 

(c)              
Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented
by the certificate, instrument or book entry so legended.

 

3.7             
Accredited Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act.

 

    15

     

    

 

3.8             
Investment Risk. THE PURCHASER ACKNOWLEDGES AND UNDERSTANDS THAT ANY INVESTMENT IN THE
COMPANY IS HIGHLY SPECULATIVE AND SUBJECT TO SUBSTANTIAL UNCERTAINTIES AND INVOLVES A HIGH DEGREE OF RISK. THE PURCHASER REPRESENTS
THAT THE PURCHASER IS ABLE, WITHOUT MATERIALLY IMPAIRING THE PURCHASER’S FINANCIAL CONDITION, TO HOLD THE SHARES AND THE
CONVERSION SHARES FOR AN INDEFINITE PERIOD OF TIME AND TO SUFFER A COMPLETE LOSS OF THE PURCHASER’S INVESTMENT.

 

3.9             
Foreign Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the
Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection
with any invitation to subscribe for the Shares or any use of this Agreement, including: (a) the legal requirements within its
jurisdiction for the purchase of the Shares; (b) any foreign exchange restrictions applicable to such purchase; (c) any governmental
or other consents that may need to be obtained and (d) the income tax and other tax consequences, if any, that may be relevant
to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription and payment for and continued
beneficial ownership of the Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

 

3.10          
No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders
or partners has either directly or indirectly, including, through a broker or finder: (a) engaged in any general solicitation;
or (b) published any advertisement in connection with the offer and sale of the Shares.

 

3.11          
Exculpation Among Purchasers. The Purchaser acknowledges that it is not relying upon any Person, other than the Company
and its officers and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither
any Purchaser nor the respective controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall
be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase
of the Shares.

 

3.12          
Residence. If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the
address of the Purchaser set forth on such Purchaser’s counterpart signature page hereto; if the Purchaser is a partnership,
corporation, limited liability company or other entity, then the office or offices of the Purchaser in which its principal place
of business is identified in the address or addresses of the Purchaser set forth on such Purchaser’s counterpart signature
page hereto.

 

3.13          
Acknowledgement of BAP Investment. The Purchaser acknowledges that the Company and BAP have entered into a Management
Services Agreement pursuant to which, among other things, BAP (or its designees) has agreed to purchase a portion of the Shares,
as described above. BAP is an entity managed by Michael Rapoport and Philip Wagenheim, which individuals also serve as Chairman
and Vice Chairman, respectively, of Broadband Capital Management, LLC, the placement agent engaged by the Company in connection
with the sale of Shares offered pursuant hereto. The Purchaser further acknowledges that Messrs. Rapoport and Wagenheim may have
a conflict of interest to the extent that Broadband Capital Management, LLC acts as placement agent in connection with the sale
of Shares offered pursuant hereto.

 

    16

     

    

 

4.           
Conditions to the Purchasers’ Obligations at Initial Closing. The obligations of each Purchaser
to purchase Shares at the Initial Closing are subject to the fulfillment, on or before the Initial Closing, of each of the following
conditions, unless otherwise waived:

 

4.1             
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall
be true and correct in all respects as of the Initial Closing.

 

4.2             
Performance. The Company shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by the Company on or before the Initial Closing.

 

4.3             
Compliance Certificate. The Executive Chair of the Company shall deliver to the Purchasers at the Initial Closing a
certificate certifying that the conditions specified in Section 4.1 and Section 4.2 have been fulfilled.

 

4.4             
Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of
the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this
Agreement shall be obtained and effective as of such Closing.

 

4.5             
Opinion of Company Counsel. Broadband Capital Management, LLC shall have received from Duane Morris LLP, counsel for
the Company, an opinion, dated as of the Initial Closing, in substantially the form of Exhibit G attached to this Agreement.

 

4.6             
Board of Directors. As of the Initial Closing, the authorized size of the Board of Directors shall be six, and the Board
of Directors shall be comprised of Greg Harriman, Jane Hollingsworth, I. Wistar Morris, Michael D. Widlitz, Michael Rapoport and
Philip Wagenheim. Michael Rapoport and Philip Wagenheim will be Broadband Directors (as defined in the Voting Agreement).

 

4.7             
Indemnification Agreements. The Company shall have executed and delivered the Indemnification Agreements.

 

4.8             
Investor Rights Agreement. The Company and each Purchaser (other than the Purchaser relying upon this condition to excuse
such Purchaser’s performance hereunder) and the other stockholders of the Company named as parties thereto shall have executed
and delivered the Investor Rights Agreement.

 

4.9             
Right of First Refusal and Co-Sale Agreement. The Company, each Purchaser (other than the Purchaser relying upon this
condition to excuse such Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto
shall have executed and delivered the Right of First Refusal and Co-Sale Agreement.

 

4.10          
Voting Agreement. The Company, each Purchaser (other than the Purchaser relying upon this condition to excuse such Purchaser’s
performance hereunder), and the other stockholders of the Company named as parties thereto shall have executed and delivered the
Voting Agreement.

 

    17

     

    

 

4.11          
Certificate. The Company shall have filed the Certificate with the Department of State of the Commonwealth of Pennsylvania
on or prior to the Initial Closing, which shall continue to be in full force and effect as of the Initial Closing.

 

4.12          
Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing a
certificate certifying: (a) the Bylaws of the Company; (b) resolutions of the Board of Directors of the Company approving the Transaction
Agreements and the transactions contemplated under the Transaction Agreements and (c) resolutions of the stockholders of the Company
approving the Certificate.

 

4.13          
Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the
Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and each Purchaser
(or its designee) shall have received all such counterpart original and certified or other copies of such documents as reasonably
requested. Such documents may include good standing certificates.

 

4.14          
Preemptive Rights. The Company shall have fully satisfied (including with respect to rights of timely notification)
or obtained enforceable waivers in respect of any preemptive or similar rights directly or indirectly affecting any of its securities.

 

4.15          
Conversion. All outstanding convertible promissory notes issued by the Company shall have been converted into shares
of Series A Preferred Stock at a conversion price of $1.50 per share and all outstanding warrants shall have been cancelled.

 

5.           
Conditions of the Company’s Obligations at Closing. The obligations of the Company to sell Shares
to the Purchasers at the Initial Closing are subject to the fulfillment, on or before the Initial Closing, of each of the following
conditions, unless otherwise waived:

 

5.1             
Representations and Warranties. The representations and warranties of each Purchaser contained in Section 3 shall
be true and correct in all respects as of the Initial Closing.

 

5.2             
Performance. The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by them on or before the Initial Closing.

 

5.3             
Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of
the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this
Agreement shall be obtained and effective as of the Initial Closing.

 

5.4             
Investor Rights Agreement. Each Purchaser shall have executed and delivered the Investor Rights Agreement.

 

5.5             
Right of First Refusal and Co-Sale Agreement. Each Purchaser and the other stockholders of the Company named as parties
thereto shall have executed and delivered the Right of First Refusal and Co-Sale Agreement.

 

    18

     

    

 

5.6             
Voting Agreement. Each Purchaser and the other stockholders of the Company named as parties thereto shall have executed
and delivered the Voting Agreement.

 

6.           
Miscellaneous.

 

6.1             
Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company
and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and
the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf
of the Purchasers or the Company.

 

6.2             
Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon
the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

6.3             
Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware,
regardless of the laws that might otherwise govern under applicable principles of conflicts of law.

 

6.4             
Counterparts. This Agreement may be executed and delivered by facsimile signature and in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may
be delivered via facsimile, electronic mail by scanned pdf of counterpart signature pages, or other such electronic means and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.5             
Conversion to Delaware Corporation. The Company shall convert to a Delaware corporation on or before the 14th day following
the Initial Closing.

 

6.6             
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement.

 

6.7             
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall
be deemed effectively given upon the earlier of actual receipt, or: (a) personal delivery to the party to be notified; (b) when
sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business
hours, then on the recipient’s next business day; (c) five days after having been sent by registered or certified mail, return
receipt requested, postage prepaid; or (d) one business day after the business day of deposit with a nationally recognized overnight
courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their address as set forth on such party’s counterpart signature page hereto, or to
such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section
6.7. If notice is given to the Company, a copy shall also be sent to Duane Morris LLP, 30 S. 17th St, Philadelphia, PA 19103,
Attn: Kathleen M. Shay (facsimile (215) 689-4382), and Sandra G. Stoneman (facsimile (215) 689-4420) and if notice is given to
BAP, a copy shall also be given Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666 Third Ave, New York, NY 10017, Attn: Evan
Bienstock (facsimile (212) 983-3115).

 

    19

     

    

 

6.8             
No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or
commission in connection with this transaction. Each Purchaser agrees to indemnify and to hold harmless the Company from any liability
for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and
the costs and expenses of defending against such liability or asserted liability) for which each Purchaser or any of its officers,
employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Purchaser from any liability
for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and
the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers,
employees or representatives is responsible.

 

6.9             
Attorneys’ Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret
the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs
and necessary disbursements in addition to any other relief to which such party may be entitled.

 

6.10          
Amendments and Waivers. Except as set forth in Section 1.1(c), any term of this Agreement may be amended, terminated
or waived only with the written consent of (a) the Company and (b) the holders of at least 662⁄3% of the then-outstanding Shares.
Any amendment or waiver effected in accordance with this Section 6.10 shall be binding upon the Purchasers and each transferee
of the Shares (or the Common Stock issuable upon conversion thereof), each future holder of all such securities, and the Company.

 

6.11          
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.

 

6.12          
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

6.13          
Entire Agreement. This Agreement (including the Exhibits hereto), the Certificate and the other Transaction Agreements
constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any
other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.

 

    20

     

    

 

6.14          
WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM
OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT
MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED
IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS
(INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED
BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS
AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES
ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

6.15          
Arbitration. Any controversy or claim arising out of or relating to this Agreement that remains unresolved for more
than 30 days after the matter is first raised by a party to the other party or parties, except as (i) otherwise provided in this
Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which
a provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator from names of potential
arbitrators proposed by the American Arbitration Association (the “AAA”) mutually agreed upon by the applicable
parties, and if no agreement can be reached within 30 days after names have been proposed by the AAA, then by one arbitrator having
reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA.
The arbitration shall take place in New Castle County, Delaware, in accordance with the AAA rules then in effect, and judgment
upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There
shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary
evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c)
such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance
with the Delaware Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for
the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official
transcript of such proceedings.

 

6.16          
No Commitment for Additional Financing. The Company acknowledges and agrees that no Purchaser has made any representation,
undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance,
other than the purchase of the Shares as set forth herein and subject to the conditions set forth herein. In addition, the Company
acknowledges and agrees that (i) no statements, whether written or oral, made by any Purchaser or its representatives on or after
the date of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any
financing or investment, (ii) the Company shall not rely on any such statement by any Purchaser or its representatives and (iii)
an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment may only be created
by a written agreement, signed by such Purchaser and the Company, setting forth the terms and conditions of such financing or investment
and stating that the parties intend for such writing to be a binding obligation or agreement. Each Purchaser shall have the right,
in its sole and absolute discretion, to refuse or decline to participate in any other financing of or investment in the Company,
and shall have no obligation to assist or cooperate with the Company in obtaining any financing, investment or other assistance.

 

(Signature pages follow.)

 

    21

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Serie A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	IMMUNOME, INC.
	 	 
	 	 
	 	By: 	/s/ Jane H. Hollingsworth
	 	Name: Jane H. Hollingsworth
	 	Title: Executive Chair
	 	 
	 	Address:
	 	 
	 	100 E. Lancaster Ave.
	 	Lankenau Institute or Medical Research
	 	Wynnewood, PA 19096

 

 

 

(Company Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	/s/
    Jonathan Auerbach
	 	Signature
	 	 
	 	Jonathan
    Auerbach
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Eisenberg
    Family Partnership
	 	Name of Purchaser (please print)
	 	 
	 	By:	/s/
    Mitchell Eisenberg
	 	 	Signature
	 	 
	 	Mitchell
    Eisenberg, President
	 	MS
    Eisenberg Holdings, Inc., General Partner
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	
	 	Purchase Price:
	 	 
	 	 
	 	
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	EMDD
	 	Name
    of Purchaser (please print)
	 	 
	 	By:	/s/
    D. Duffy
	 	 	Signature
	 	 
	 	D. Duffy
	 	(print
    name and title of signatory)
	 	 
	 	Number
    of Shares:
	 	 
	 	 
	 	 
	 	Purchase
    Price:
	 	 
	 	 
	 	 
	 	Address
    and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	/s/ David W. Freelove
	 	Signature
	 	 
	 	David W. Freelove
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	G-TEN PARTNERS LLC
	 	Name of Purchaser (please print)
	 	 
	 	By:	/s/ Jaime Hartman
	 	 	Signature
	 	 
	 	Jaime Hartman, Managing Member
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	GENESIS ASSET OPPORTUNITY FUND
    LP
	 	Name of Purchaser (please print)
	 	 
	 	By:	/s/ Jaime Hartman
	 	 	Signature
	 	 
	 	Jaime Hartman, Managing Member
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

 

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	HUG FUNDING LLC
	 	Name of Purchaser (please print)
	 	 
	 	By: 	/s/ Jaime Hartman
	 	Signature
	 	 
	 	Jaime Hartman, Managing Member
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	HVA Ltd Partnership
	 	Name of Purchaser (please print)
	 	 
	 	By: 	/s/ Harold Van Arnem
	 	Signature
	 	 
	 	Harold Van Arnem, President, HVA Corp, Managing Partner
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
Scott Klansky
	 	Signature
	 	 
	 	Scott Klansky
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Matthew M. Kremer
	 	Signature
	 	 
	 	Matthew M. Kremer
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

  

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Ken Koch
	 	Signature
	 	 
	 	Ken Koch
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Shawn Langer
	 	Signature
	 	 
	 	Shawn Langer
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ David D. Langfitt
	 	Signature
	 	 
	 	David D. Langfitt
	 	Name
	 	 
	 	 /s/ Margaret B. Langfitt
	 	Signature
    (if more than one)*
	 	 
	 	 Margaret B. Langfitt
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Jonathon Lawrie
	 	Signature
	 	 
	 	Jonathon Lawrie
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Roland J. Lewis
	 	Signature
	 	 
	 	Roland J. Lewis III
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Bruce E. Maryanoff
	 	Signature
	 	 
	 	Bruce E. Maryanoff
	 	Name
	 	 
	 	/s/ Cynthia A. Maryanoff
	 	Signature
    (if more than one)*
	 	 
	 	Cynthia A. Maryanoff
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Monoclonal Antibodies, LLC
	 	Name of Purchaser (please print)
	 	 
	 	By: 	/s/ David W. Freelove
	 	Signature
	 	 
	 	David W. Freelove
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

  

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred
Stock Purchase Agreement)

 

    

     

    

 

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ I. Wistar Morris
	 	Signature
	 	 
	 	I. Wistar Morris
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)

 

	 	By: 	 
	 	 	Signature

 

	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Richard Pigossi
	 	Signature
	 	 
	 	Richard Pigossi
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)

 

	 	By: 	 
	 	 	Signature

 

	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Eric Raphael
	 	Signature
	 	 
	 	Eric Raphael
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)

 

	 	By:	 
	 	 	Signature

 

	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Robin Hood Ventures 54 L.P.
	 	Name of Purchaser (please print)
	 	 
	 	By: 	/s/ Ellen Weber 
	 	Signature
	 	  
	 	Robin Hood Ventures Management IV Inc., HSGP, Ellen Weber, Secretary
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Robert Rothstein
	 	Signature
	 	 
	 	Robert Rothstein
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	               
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

   

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ David Rosenberg
	 	Signature
	 	 
	 	David Rosenberg
	 	Name
	 	 
	 	/s/ Dara
    Rosenberg
	 	Signature
    (if more than one)*
	 	 
	 	 Dara Rosenberg
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Thomas M. Ryan
	 	Signature
	 	 
	 	Thomas M. Ryan
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

  

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Louis P. Wagman
	 	Signature
	 	 
	 	Louis
    P. Wagman
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By:
    	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase
    Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Michael Widlitz
	 	Signature
	 	 
	 	Michael Widlitz
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	THE WOODLAND TRUST
	 	Name of Purchaser (please print)
	 	 
	 	By: 	/s/ Bruno Schwendinger    
	 	Signature
	 	 
	 	/s/ Bruno SCHWENDINGER, Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

  

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Deborah J. Ziskin
	 	Signature
	 	 
	 	Deborah J. Ziskin
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Series A Preferred Stock Purchase Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/ Donald Zoltan
	 	Signature
	 	 
	 	Donald Zoltan
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By: 	                 
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

  

*If joint purchasers, both must
sign.

 

(Purchaser Signature Page to Immunome, Inc. Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

 

EXHIBIT A

 

FORM OF SECOND AMENDED
AND RESTATED ARTICLES OF INCORPORATION

 

    A-1

     

    

 

EXHIBIT B

 

DISCLOSURE SCHEDULE

 

    B-1

     

    

 

EXHIBIT C

 

FORM OF INDEMNIFICATION
AGREEMENT

 

    C-1

     

    

 

EXHIBIT D

 

FORM OF INVESTOR RIGHTS
AGREEMENT

 

    D-1

     

    

 

EXHIBIT E

 

FORM OF RIGHT OF FIRST
REFUSAL AND CO-SALE AGREEMENT

 

    E-1

     

    

 

EXHIBIT F

 

FORM OF VOTING AGREEMENT

 

    F-1

     

    

 

EXHIBIT G

 

FORM OF LEGAL OPINION
OF DUANE MORRIS LLP

 

    G-1

     

    

 

AMENDMENT TO

SERIES A PREFERRED STOCK PURCHASE AGREEMENT

 

THIS AMENDMENT (this “Amendment”)
is entered into effective as of December 14, 2015 by and among Immunome, Inc. (the “Company”), a Delaware corporation,
and the undersigned holders of the Company’s outstanding Series A Convertible Preferred Stock (the “Holders”).
This Amendment amends the Series A Preferred Stock Purchase Agreement dated as of November 18, 2015 among the Company and the purchasers
who are parties thereto (the “Purchase Agreement”). All capitalized terms used in this Amendment without definition
shall have the respective meanings assigned to them in the Purchase Agreement.

 

Background:

 

Pursuant to Section 6.10
of the Purchase Agreement, the Purchase Agreement may be amended or modified, if the Company and the holders of at least 662⁄3%
of the then-outstanding Shares consent thereto. The Holders hold Shares sufficient to satisfy the foregoing requirement to amend
the Purchase Agreement and, by virtue of the execution and delivery of this Amendment, the agreements in this Amendment will apply
to and be binding upon the Company and all of the Purchasers.

 

Pursuant to the Purchase
Agreement, the Purchasers purchased shares of Series A Preferred Stock from the Company at the Initial Closing thereunder. Section
1.3 of the Purchase Agreement provides that the Company may sell Additional Shares of Series A Preferred Stock to Additional Purchasers
at one or more Closings to occur on or prior to December 15, 2015. The Company and the Holders wish to amend the Purchase Agreement
to extend the date by which such additional Closings must occur.

 

NOW, THEREFORE, in consideration
of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.            Amendment
to Purchase Agreement. Section 1.3 of the Purchase Agreement is hereby amended and restated to provide in its entirety as follows:

 

“1.3
Sale of Shares of Series A Preferred Stock at Additional Closings. At one or more Closings to occur on or prior to February
29, 2016, the Company may sell, on the same terms and conditions as those contained in this Agreement, additional Shares in an
aggregate amount equal to $5,000,000 in Shares less the number of Shares issued and sold at the Initial Closing (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or similar recapitalization affecting such shares) (the
 “Additional Shares”), to one or more purchasers reasonably acceptable to the Board of Directors of the Company
(the “Additional Purchasers”) (it is hereby acknowledged that holders of convertible promissory notes being
converted on November 18, 2015 purchasing in the aggregate up to $166,000 in Shares are reasonably acceptable); provided, that:
(a) each Additional Purchaser who is not already a party thereto shall become a party to the Transaction Agreements (as defined
below), by executing and delivering a counterpart signature page to, or other agreement satisfactory to the Company agreeing to
be bound by, each of the Transaction Agreements; and (b) at a Closing to be completed on February 29, 2016, BCM Advisory Partners,
LLC (“BAP”) and/or its designees reasonably acceptable to the Board of Directors of the Company shall purchase
that number of Additional Shares equal to the number of Additional Shares that were not purchased, or are not on that date being
purchased, by other Additional Purchasers.”

 

    1

     

    

 

2.            Effect
of Amendment. The parties acknowledge and agree that all of the terms, provisions, covenants and conditions of the Purchase
Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the extent expressly
modified, amended or revised herein; provided, however, that if any term or provision of this Amendment shall conflict with or
otherwise be inconsistent with any term or provision of any of the Purchase Agreement, the terms and provisions of this Amendment
shall prevail.

 

3.            Governing
Law. This Amendment shall be governed by and construed under the laws of the State of Delaware, without giving effect to principles
of conflicts of laws.

 

4.            Counterparts.
This Amendment may be executed (by facsimile) in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

 

(Signature page follows.)

 

    2

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Amendment as of the date first above written.

 

		IMMUNOME, INC.
		 	 
		By:	/s/ Jane H. Hollingsworth
		Name:	Jane H. Hollingsworth

Title: Executive Chair and CEO

 

(Company Signature Page
to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ I. Wistar Morris
	 	Signature
	 	 
	 	I. Wistar Morris
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement
    Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page
to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

	 	Individuals Sign Below:
	 
	 	/s/ David W. Freelove
	 	Signature
	 
	 	David W. Freelove
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 
	 	Name (if more than one)*
	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign
Below:
	 
	 
	 	Name of Purchaser (please print)
	 
	 	By:	 	 	 	 	 	 	 	 	 	 	 
	 	 	Signature
	 
	 	 
	 	(print name and title of signatory)
	 
	 	Number of Shares:
	 	 
	 	 
	 
	 	Purchase Price:
	 	 
	 	 
	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement
    Accounts or Other Entities Sign Below:
	 	 
	 	GENESIS ASSET OPPORTUNITY FUND LP
	 	Name of Purchaser (please print)
	 	 
	 	 
	 	By:	 /s/ Jaime Hartman
	 	 	Signature
	 	 
	 	Jaime Hartman, Portfolio Manager
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement
    Accounts or Other Entities Sign Below:
	 	 
	 	G-TEN PARTNERS LLC
	 	Name of Purchaser (please print)
	 	 
	 	By:	/s/ Jaime Hartman
	 	 	Signature
	 	 
	 	Jaime Hartman, Managing Member
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement
    Accounts or Other Entities Sign Below:
	 	 
	 	HUG FUNDING LLC
	 	Name of Purchaser (please print)
	 	 
	 	By:	/s/ Jaime Hartman
	 	 	Signature
	 	 
	 	Jaime Hartman, Managing Manager
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
undersigned has caused this Amendment as of the date first above written.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Donald Zoltan
	 	Signature
	 	 
	 	Donald Zoltan
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement
    Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Purchaser (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Number of Shares:
	 	 
	 	 
	 	 
	 	Purchase Price:
	 	 
	 	 
	 	 
	 	Address and Facsimile:
	 	 
	 	 
	 	 
	 	 

 

*If joint purchasers,
both must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

AMENDMENT TO

SERIES A PREFERRED STOCK PURCHASE AGREEMENT

 

THIS AMENDMENT
(this “Amendment”) is entered into effective as of August 5, 2020 by and among Immunome, Inc. (the “Company”),
a Delaware corporation, and the undersigned holders of the Company’s outstanding Series A Convertible Preferred Stock (the
 “Holders”). This Amendment amends the Series A Preferred Stock Purchase Agreement dated as of November 18, 2015 among
the Company and the purchasers who are parties thereto, as amended (the “Purchase Agreement”). All capitalized terms
used in this Amendment without definition shall have the respective meanings assigned to them in the Purchase Agreement.

 

Background:

 

The Company and the Holders wish to amend
the Purchase Agreement as provided below. The Holders hold Shares sufficient to satisfy the foregoing requirement to amend the
Purchase Agreement and, by virtue of the execution and delivery of this Amendment, the agreements in this Amendment will apply
to and be binding upon the Company and all of the Purchasers.

 

NOW,
THEREFORE, in consideration of the premises and covenants set forth herein,
and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.            Amendment
to Section 1.4 of Purchase Agreement.1. Section 1.4 of the Purchase Agreement is hereby amended and restated to provide in
its entirety as follows:

 

1.4      Sale
of Shares of Series A Preferred Stock at Milestone Closing.

 

(a)       Within
10 days after achievement of the Milestone Events (as defined below), the Company shall deliver to BAP and the Purchasers a written
notice (the “Milestone Closing Notice”) that an additional Closing pursuant to this Section 1.4 (the
 “Milestone Closing”) will be consummated and specifying the date thereof, which shall be not less than 15 days
and not more than 45 days following the date that the Milestone Closing Notice is delivered; provided, however, that the Company
may delay the Milestone Closing to a date that is up to 135 days following the date that the Milestone Closing Notice is delivered
if the Company determines that it would need to make any public disclosure not already made public by the Company prior to or in
connection with any sale of securities in order to comply with applicable securities laws, rules and regulations. At the Milestone
Closing, the Company shall sell, on the same terms and conditions as those contained in this Agreement, an aggregate of 2,333,333
additional shares of Series A Preferred Stock (the “Milestone Shares”), to one or more purchasers (“Milestone
Purchasers”) at a purchase price per Milestone Share equal to the Purchase Price. The Milestone Shares will be allocated
among the Milestone Purchasers as follows: (a) each existing Purchaser will have the right to purchase up to that portion of 1,666,666
Milestone Shares determined based upon each such Purchaser’s pro rata ownership of the Shares held by all Purchasers, with
an oversubscription right for fully participating Purchasers; (b) BAP shall allocate any remaining Milestone Shares among any other
purchaser(s); and (c) BAP and/or its designees will purchase 666,667 Milestone Shares plus any Milestone Shares that remain unallocated
after the application of clauses (a) and (b). All share amounts in this paragraph are subject to appropriate adjustment in the
event of any stock dividend, stock split, combination or similar recapitalization affecting such shares.

 

    

     

    

 

(b)       In the event that all
outstanding shares of Series A Preferred Stock are converted into Common Stock prior to the occurrence of the Milestone Closing,
then: (a) the Milestone Shares shall be shares of Common Stock instead of shares of Series A Preferred Stock and (b) the pro rata
calculation of each Purchaser’s purchase right shall be determined based on such Purchaser’s pro rata ownership of
the shares of Common Stock issued upon conversion of the Shares.

 

(c)       Each
Milestone Purchaser who is not already a party thereto shall become a party to the Transaction Agreements, to the extent that such
Transaction Agreements are then in effect, by executing and delivering a counterpart signature page to, or other agreement satisfactory
to the Company agreeing to be bound by, each of the Transaction Agreements.

 

2.                 
Amendment to Section 1.5(j). Section 1.5(j) shall be amended and restated in its entirety
so as to provide as follows:

 

(j)        “Milestone
Events” means: (i) receipt by the Company of positive safety and efficacy data in animal testing in respect of at least
one of the Company’s lead product candidates; (ii) appointment of three new members of the Company’s Scientific
Advisory Board, mutually agreed by the Board of Directors of the Company and BAP; and (iii) receipt by the Company of at least
$10,000,000 in non-dilutive proceeds pursuant to a definitive agreement entered into between the Company and a strategic partner
approved by the Board of Directors. It is hereby acknowledged that the Milestone Events in clauses (i) and (ii) have been satisfied.

 

3.            Amendment to Section 6.2. Section 6.2 shall be amended and restated in its entirety so
as to provide as follows:

 

6.2      Successors
and Assigns. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by such Purchaser
only to (a) any Person to which Shares are transferred by such Purchaser, or (b) any Affiliate of such Purchaser, and, in each
case, such transferee shall be deemed a “Purchaser” for purposes of this Agreement; provided, that (i) each such assignment
of rights shall be contingent upon the transferee providing a written instrument to the Company notifying the Company of such transfer
and assignment and agreeing in writing to be bound by the terms of this Agreement, and (ii) the Company shall not be required to
recognize or effect any such assignment if it would violate applicable securities laws or would not be exempt from registration
under the Securities Act of 1933, as amended, as determined by the Company. The Company may not assign its rights under this Agreement.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. Any attempted assignment in violation of this Section 6.2 is null and void.

 

    2

     

    

 

4.            Confirmation. It is hereby confirmed that the date by which Additional Closings may be
completed was previously extended to April 12, 2016.

 

5.            Effect of Amendment.2. The parties acknowledge and agree that all of the terms, provisions, covenants and conditions
of the Purchase Agreement shall hereafter continue in full force and effect in accordance with the terms thereof, except to the
extent expressly modified, amended or revised herein; provided, however, that if any term or provision of this Amendment shall
conflict with or otherwise be inconsistent with any term or provision of any of the Purchase Agreement, the terms and provisions
of this Amendment shall prevail.

 

6.            Governing Law.3. This Amendment shall be governed by and construed under the laws of the State of Delaware, without
giving effect to principles of conflicts of laws.

 

7.            Counterparts.4.
This Amendment may be executed (by facsimile) in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

(Signature page follows.)

 

    3

     

    

 

IN WITNESS
WHEREOF, the parties hereto have executed this Amendment as of the date first above written. 

 

	 	IMMUNOME, INC.
	 	 
	 	By:	 
	 	 	Name:	Purnanand Sarma
	 	 	Title:	CEO and President

 

(Company Signature Page
to Amendment to

Series A Preferred Stock Purchase Agreement)

 

    

     

    

 

IN WITNESS
WHEREOF, the undersigned has caused this Amendment to be executed as of the date first above written.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Entity
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	Name and Title of Signatory

 

*If joint holders, both
must sign.

 

(Holder Signature Page to Amendment to

Series A Preferred Stock Purchase Agreement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]